Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Gynecology

  Free Subscription


Articles published in Gynecol Oncol

Retrieve available abstracts of 783 articles:
HTML format



Single Articles


    August 2022
  1. DEMARI JA, Shalowitz DI
    Routine informed consent for mismatch repair testing in endometrial cancers: Review and ethical analysis.
    Gynecol Oncol. 2022 Aug 8. pii: S0090-8258(22)00540.
    PubMed     Abstract available


  2. MOSS KM, Mishra GD, Krejany EO, Hickey M, et al
    What happens after menopause? (WHAM): A prospective controlled study of symptom profiles up to 12 months after pre-menopausal risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2022 Aug 3. pii: S0090-8258(22)00513.
    PubMed     Abstract available


  3. ZHAO L, Qin Y, Ma D, Liu H, et al
    Surgical treatment of lung metastasis in patients with refractory gestational trophoblastic neoplasia: A retrospective study.
    Gynecol Oncol. 2022 Aug 2. pii: S0090-8258(22)00514.
    PubMed     Abstract available


  4. KUMAR A, Wang C, Sheedy SP, McCauley BM, et al
    Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer.
    Gynecol Oncol. 2022 Aug 2. pii: S0090-8258(22)00492.
    PubMed     Abstract available


  5. SHAPIRA-FROMMER R, Mileshkin L, Manzyuk L, Penel N, et al
    Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study.
    Gynecol Oncol. 2022;166:211-218.
    PubMed     Abstract available


  6. SHIM JI, Ryu JY, Jeong SY, Cho YJ, et al
    Corrigendum to "Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer" [Gynecologic Oncology, Volume 165, Issue 2, May 2022, Pages 270-280].
    Gynecol Oncol. 2022;166:370-371.
    PubMed    


  7. MARION S, Aviki E, Chino F
    Financial toxicity of surgical treatment for gynecological cancer: A growing malignancy.
    Gynecol Oncol. 2022;166:197-199.
    PubMed    


    July 2022
  8. SIVARS L, Hellman K, Crona Guterstam Y, Holzhauser S, et al
    Circulating cell-free tumor human papillomavirus DNA is a promising biomarker in cervical cancer.
    Gynecol Oncol. 2022 Jul 30. pii: S0090-8258(22)00512.
    PubMed     Abstract available


  9. HOARE JI, Hockings H, Saxena J, Silva VL, et al
    A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
    Gynecol Oncol. 2022 Jul 30. pii: S0090-8258(22)00511.
    PubMed     Abstract available


  10. ALHOLM Z, He D, Ting J, Zhang YJ, et al
    Real-world treatment drop-off among recurrent or metastatic cervical cancer patients: A US community oncology-based analysis.
    Gynecol Oncol. 2022 Jul 29. pii: S0090-8258(22)00509.
    PubMed     Abstract available


  11. SHRESTHA P, Poudyal B, Yadollahi S, E Wright D, et al
    A systematic review on the use of artificial intelligence in gynecologic imaging - Background, state of the art, and future directions.
    Gynecol Oncol. 2022 Jul 29. pii: S0090-8258(22)00496.
    PubMed     Abstract available


  12. BOGANI G, Donato VD, Scambia G, Landoni F, et al
    Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer.
    Gynecol Oncol. 2022 Jul 28. pii: S0090-8258(22)00494.
    PubMed     Abstract available


  13. LEWIS GK, Ghaith S, Craver EC, Li Z, et al
    The association of endosalpingiosis with gynecologic malignancy.
    Gynecol Oncol. 2022 Jul 28. pii: S0090-8258(22)00510.
    PubMed     Abstract available


  14. BARRINGTON DA, Calo C, Baek J, Brown M, et al
    Beyond mismatch repair deficiency? Pre-treatment neutrophil-to-lymphocyte ratio is associated with improved overall survival in patients with recurrent endometrial cancer treated with immunotherapy.
    Gynecol Oncol. 2022 Jul 27. pii: S0090-8258(22)00482.
    PubMed     Abstract available


  15. KIM YN, Lee D, Cha J, Kang WJ, et al
    Usefulness and potential pitfalls of pre-operative PET-CT in patients with endometrial cancer undergoing one- and two-step sentinel lymph node mapping: Do negative findings on PET-CT negativity really indicate node negativity?
    Gynecol Oncol. 2022 Jul 27. pii: S0090-8258(22)00487.
    PubMed     Abstract available


  16. JOLY F, Fabbro M, Berton D, Lequesne J, et al
    Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
    Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00426.
    PubMed     Abstract available


  17. LIANG MI, Simons JL, Herbey I, Wall JA, et al
    Navigating job and cancer demands during treatment: A qualitative study of ovarian cancer patients.
    Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00493.
    PubMed     Abstract available



  18. The implications of the loss of abortion services from the perspective of the gynecologic cancer care team.
    Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00491.
    PubMed    


  19. BARRINGTON DA, Meade CE, Cosgrove CM, Cohn DE, et al
    Racial and ethnic disparities in readmission risk following the surgical management of endometrial cancer.
    Gynecol Oncol. 2022 Jul 23. pii: S0090-8258(22)00486.
    PubMed     Abstract available


  20. SHALOWITZ DI, Charlton ME
    The road to geographic equity in access to gynecologic cancer care.
    Gynecol Oncol. 2022 Jul 22. pii: S0090-8258(22)00490.
    PubMed    


  21. LEITAO MM JR, Zhou QC, Brandt B, Iasonos A, et al
    The MEMORY Study: MulticentEr study of Minimally invasive surgery versus Open Radical hYsterectomy in the management of early-stage cervical cancer: Survival outcomes.
    Gynecol Oncol. 2022 Jul 22. pii: S0090-8258(22)00434.
    PubMed     Abstract available


  22. LEVINE MD, Barrington DA, Hampel H, Goodfellow PJ, et al
    Implementing universal upfront multi-gene panel testing in endometrial cancer: From cost to practical considerations.
    Gynecol Oncol. 2022 Jul 20. pii: S0090-8258(22)00488.
    PubMed     Abstract available


  23. LI H, Wang S, Liu Y, Wang T, et al
    Prophylactic extended-field irradiation for locally advanced cervical cancer.
    Gynecol Oncol. 2022 Jul 19. pii: S0090-8258(22)00481.
    PubMed     Abstract available


  24. TUCKER K, Sullivan S, Deal AM, Allman K, et al
    A prospective randomized trial of standard versus multimedia-supplemented counseling in patients undergoing endometrial cancer staging surgery.
    Gynecol Oncol. 2022 Jul 18. pii: S0090-8258(22)00485.
    PubMed     Abstract available


  25. ALHILLI MM, Schold JD, Kelley J, Tang AS, et al
    Preoperative assessment using the five-factor modified frailty index: A call for standardized preoperative assessment and prehabilitation services in gynecologic oncology.
    Gynecol Oncol. 2022 Jul 18. pii: S0090-8258(22)00435.
    PubMed     Abstract available


  26. KIM SI, Kim JH, Noh JJ, Kim SH, et al
    Impact of bevacizumab and secondary cytoreductive surgery on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma: A multicenter study in Korea.
    Gynecol Oncol. 2022 Jul 18. pii: S0090-8258(22)00483.
    PubMed     Abstract available


  27. CHASE DM, Marin MR, Backes F, Han S, et al
    Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial.
    Gynecol Oncol. 2022 Jul 15. pii: S0090-8258(22)00432.
    PubMed     Abstract available


  28. BENICHOU J, Schwall C, Sastre-Garau X, Mereaux J, et al
    Impact of the new molecular classification of endometrial cancer: A French cohort study.
    Gynecol Oncol. 2022 Jul 14. pii: S0090-8258(22)00484.
    PubMed     Abstract available


  29. HARE CJ, Crangle C, McGarragle K, Ferguson SE, et al
    Change in cancer-related fatigue over time predict health-related quality of life in ovarian cancer patients.
    Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00433.
    PubMed     Abstract available


  30. PITIYARACHCHI O, Friedlander M, Java JJ, Chan JK, et al
    What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (>/=10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemothera
    Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00436.
    PubMed     Abstract available


  31. O'MALLEY DM, Bariani GM, Cassier PA, Marabelle A, et al
    Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study.
    Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00405.
    PubMed     Abstract available


  32. PIEDIMONTE S, Bernardini MQ, Ding A, Laframboise S, et al
    Integrated prediction model of patient factors, resectability scores and surgical complexity to predict cytoreductive outcome and guide treatment plan in advanced ovarian cancer.
    Gynecol Oncol. 2022 Jul 9. pii: S0090-8258(22)00430.
    PubMed     Abstract available


  33. MCDONALD V, Wang Y, Patel A, Betcher R, et al
    Laparoscopic guided liposomal bupivacaine injection compared to transversus abdominus plane block for postoperative pain after robotic gynecologic oncology surgery.
    Gynecol Oncol. 2022 Jul 8. pii: S0090-8258(22)00406.
    PubMed     Abstract available


  34. CADOO K, Simpkins F, Mathews C, Liu YL, et al
    Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
    Gynecol Oncol. 2022 Jul 5. pii: S0090-8258(22)00421.
    PubMed     Abstract available


  35. TSENG JH, Bristow RE
    Complications associated with cytoreductive surgery for advanced ovarian cancer: Surgical timing and surmounting obstacles.
    Gynecol Oncol. 2022;166:5-7.
    PubMed    


  36. HANDLEY KF, Sood AK, Molin GZD, Westin SN, et al
    Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes.
    Gynecol Oncol. 2022;166:50-56.
    PubMed     Abstract available


  37. MOKHTECH M, Gao SJ, Kassick M, Menderes G, et al
    Declining use of inguinofemoral lymphadenectomy in the treatment of clinically negative, pathologic node positive vulvar cancer.
    Gynecol Oncol. 2022;166:61-68.
    PubMed     Abstract available


  38. O'CEARBHAILL RE, Perez-Fidalgo JA, Monk BJ, Tusquets I, et al
    Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
    Gynecol Oncol. 2022;166:36-43.
    PubMed     Abstract available


  39. NELSON G
    Social media in gynecologic oncology: A new frontier.
    Gynecol Oncol. 2022;166:3-4.
    PubMed    


  40. GEHRIG PA, Farley J
    Introducing a new series in Gynecologic Oncology: Health equity in gynecologic oncology research.
    Gynecol Oncol. 2022;166:1-2.
    PubMed    


  41. CHERSTON C, Yoh K, Huang Y, Melamed A, et al
    Relative importance of individual insurance status and hospital payer mix on survival for women with cervical cancer.
    Gynecol Oncol. 2022 Jul 1. pii: S0090-8258(22)00427.
    PubMed     Abstract available


    June 2022
  42. LIU K, Zhu Y, Zhou Y, Zhang Y, et al
    Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis.
    Gynecol Oncol. 2022 Jun 30. pii: S0090-8258(22)00419.
    PubMed     Abstract available


  43. MUNOZ JL, Blankenship LM, Ramsey PS, McCann GA, et al
    Importance of the gynecologic oncologist in management of cesarean hysterectomy for Placenta Accreta Spectrum (PAS).
    Gynecol Oncol. 2022 Jun 30. pii: S0090-8258(22)00429.
    PubMed     Abstract available


  44. SY F, Greuel M, Winkler V, Bussmann H, et al
    Accuracy of HPV testing on self-collected and clinician-collected samples for different screening strategies in African settings: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Jun 30. pii: S0090-8258(22)00416.
    PubMed     Abstract available


  45. WALL JA, Lipking K, Smith HJ, Huh WK, et al
    Moderate to severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management.
    Gynecol Oncol. 2022 Jun 28. pii: S0090-8258(22)00420.
    PubMed     Abstract available


  46. ROGOWSKI P, Rottler M, Walter F, Saicic S, et al
    Clinical outcome of combined intracavitary / interstitial brachytherapy using a hybrid applicator in locally advanced cervical cancer.
    Gynecol Oncol. 2022 Jun 25. pii: S0090-8258(22)00423.
    PubMed     Abstract available


  47. BACORRO W, Baldivia K, Yu KK, Mariano J, et al
    Outcomes with definitive radiotherapy among patients with locally advanced cervical cancer with relative or absolute contraindications to cisplatin: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Jun 24. pii: S0090-8258(22)00422.
    PubMed     Abstract available


  48. HEFFERNAN K, Nikitas FS, Shukla U, Camejo HS, et al
    Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis.
    Gynecol Oncol. 2022 Jun 22. pii: S0090-8258(22)00415.
    PubMed     Abstract available


  49. DICKEN BJ, Billmire DF, Rich B, Hazard FK, et al
    Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group.
    Gynecol Oncol. 2022 Jun 21. pii: S0090-8258(22)00417.
    PubMed     Abstract available


  50. KEUNECKE C, Kulbe H, Dreher F, Taube ET, et al
    Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
    Gynecol Oncol. 2022 Jun 20. pii: S0090-8258(22)00414.
    PubMed     Abstract available


  51. AO M, Zheng D, Wang J, Gu X, et al
    Corrigendum to "Risk factors analysis of persistence, progression and recurrence in vaginal intraepithelial neoplasia" [Gynecologic Oncology, Volume 162, Issue 3, September 2021, Pages 584-589].
    Gynecol Oncol. 2022 Jun 20. pii: S0090-8258(22)00411.
    PubMed    


  52. KIM NR, Lee AJ, Yang EJ, So KA, et al
    Minimally invasive surgery versus open surgery in high-risk histologic endometrial cancer patients: A meta-analysis.
    Gynecol Oncol. 2022 Jun 17. pii: S0090-8258(22)00404.
    PubMed     Abstract available


  53. BOGANI G, Di Donato V, Papadia A, Buda A, et al
    Evaluating long-term outcomes of three approaches to retroperitoneal staging in endometrial cancer.
    Gynecol Oncol. 2022 Jun 17. pii: S0090-8258(22)00407.
    PubMed     Abstract available


  54. CAMPBELL R, Costa DSJ, Stockler MR, Lee YC, et al
    Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
    Gynecol Oncol. 2022 Jun 16. pii: S0090-8258(22)00335.
    PubMed     Abstract available


  55. JERNIGAN A, Farley J, Walsh C
    Highlights from the 2022 Society of Gynecologic Oncology Annual Meeting on Women's Cancer.
    Gynecol Oncol. 2022 Jun 15. pii: S0090-8258(22)00410.
    PubMed    


  56. NAKAMURA K, Shigeyasu K, Okamoto K, Matsuoka H, et al
    ADAR1 and AZIN1 RNA editing function as an oncogene and contributes to immortalization in endometrial cancer.
    Gynecol Oncol. 2022 Jun 10. pii: S0090-8258(22)00337.
    PubMed     Abstract available


  57. HEALD B, Mokhtary S, Nielsen SM, Rojahn S, et al
    Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer.
    Gynecol Oncol. 2022 Jun 9. pii: S0090-8258(22)00334.
    PubMed     Abstract available


  58. SCHIFF JP, Mintz R, Cohen AC, Huang Y, et al
    Overall survival in patients with FIGO stage IVA cervical cancer.
    Gynecol Oncol. 2022 Jun 9. pii: S0090-8258(22)00333.
    PubMed     Abstract available


  59. HARDESTY MM, Krivak TC, Wright GS, Hamilton E, et al
    OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
    Gynecol Oncol. 2022 Jun 8. pii: S0090-8258(22)00331.
    PubMed     Abstract available


  60. LOF P, van de Vrie R, Korse CM, van Gent MDJM, et al
    Can serum human epididymis protein 4 (HE4) support the decision to refer a patient with an ovarian mass to an oncology hospital?
    Gynecol Oncol. 2022 Jun 7. pii: S0090-8258(22)00336.
    PubMed     Abstract available


  61. ZHOU N, Cui Y, Zhu R, Kuang Y, et al
    Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo.
    Gynecol Oncol. 2022 Jun 7. pii: S0090-8258(22)00306.
    PubMed     Abstract available


  62. HORSBOL TA, Kjaer SK, Andersen EW, Ammitzboll G, et al
    Use of hypnotics among women diagnosed with cervical cancer - A population-based cohort study.
    Gynecol Oncol. 2022 Jun 6. pii: S0090-8258(22)00330.
    PubMed     Abstract available


  63. NASIOUDIS D, Mastroyannis SA, Ko EM, Haggerty AF, et al
    Delay in adjuvant chemotherapy administration for patients with FIGO stage I epithelial ovarian carcinoma is associated with worse survival; an analysis of the National Cancer Database.
    Gynecol Oncol. 2022 Jun 3. pii: S0090-8258(22)00314.
    PubMed     Abstract available


  64. DIGGS A, Sia TY, Huang Y, Gockley A, et al
    Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma.
    Gynecol Oncol. 2022 Jun 2. pii: S0090-8258(22)00329.
    PubMed     Abstract available


  65. GERSHENSON DM, Sun CC, Westin SN, Eyada M, et al
    The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.
    Gynecol Oncol. 2022;165:560-567.
    PubMed     Abstract available


  66. MARTIN AL, Sinha S, Peres LC, Hakam A, et al
    The impact of distance to closest negative margin on survival after pelvic exenteration.
    Gynecol Oncol. 2022;165:514-521.
    PubMed     Abstract available


  67. SCHNACK TH, Froeding LP, Kristensen E, Niemann I, et al
    Preoperative predictors of inguinal lymph node metastases in vulvar cancer - A nationwide study.
    Gynecol Oncol. 2022;165:420-427.
    PubMed     Abstract available


  68. HOU X, Zhai Y, Hu K, Liu CJ, et al
    Aging accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma.
    Gynecol Oncol. 2022;165:552-559.
    PubMed     Abstract available


  69. FELIX AS, Addison D
    The intersection of gynecologic cancer, obesity, and cardiovascular disease.
    Gynecol Oncol. 2022;165:403-404.
    PubMed    


  70. NG AP, Sanaiha Y, Verma A, Lee C, et al
    Insurance-based disparities and risk of financial toxicity among patients undergoing gynecologic cancer operations.
    Gynecol Oncol. 2022 Jun 1. pii: S0090-8258(22)00328.
    PubMed     Abstract available


    May 2022
  71. YADAV G, Roque DM, Bellone S, Manavella DD, et al
    Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.
    Gynecol Oncol. 2022 May 28. pii: S0090-8258(22)00332.
    PubMed     Abstract available


  72. PIEDIMONTE S, Pond GR, Plante M, Nelson G, et al
    Comparison of outcomes between abdominal, minimally invasive and combined vaginal-laparoscopic hysterectomy in patients with stage IAI/IA2 cervical cancer: 4C (Canadian Cervical Cancer Collaborative) study.
    Gynecol Oncol. 2022 May 26. pii: S0090-8258(22)00310.
    PubMed     Abstract available


  73. GORGEU V, Borghese B, Koual M, Just PA, et al
    Potential competing risk of death in older high-risk endometrial carcinoma patients: Results from a multicentric retrospective cohort.
    Gynecol Oncol. 2022 May 25. pii: S0090-8258(22)00321.
    PubMed     Abstract available


  74. NOLIN AC, Tian C, Hamilton CA, Casablanca Y, et al
    Conditional estimates for uterine serous cancer: Tools for survivorship counseling and planning.
    Gynecol Oncol. 2022 May 24. pii: S0090-8258(22)00312.
    PubMed     Abstract available


  75. BROEKMAN KE, van der Aa MA, Nijman HW, Jalving M, et al
    End-of-life care for patients with advanced ovarian cancer in the Netherlands: A retrospective registry-based analysis.
    Gynecol Oncol. 2022 May 23. pii: S0090-8258(22)00258.
    PubMed     Abstract available


  76. GENNARI P, Tchaikovski S, Meszaros J, Gerken M, et al
    Protective effect of pre-operative conization in patients undergoing surgical treatment for early-stage cervical cancer.
    Gynecol Oncol. 2022 May 23. pii: S0090-8258(22)00313.
    PubMed     Abstract available


  77. MAH SJ, Anpalagan T, Marcucci M, Eiriksson L, et al
    The five-factor modified frailty index predicts adverse postoperative and chemotherapy outcomes in gynecologic oncology.
    Gynecol Oncol. 2022 May 20. pii: S0090-8258(22)00311.
    PubMed     Abstract available


  78. TYMON-ROSARIO JR, Manara P, Manavella DD, Bellone S, et al
    Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
    Gynecol Oncol. 2022 May 19. pii: S0090-8258(22)00305.
    PubMed     Abstract available


  79. MARSH LA, Aviki EM, Wright JD, Chen L, et al
    Sentinel lymph node mapping for endometrial cancer: Opportunity for medical waste reform.
    Gynecol Oncol. 2022 May 18. pii: S0090-8258(22)00308.
    PubMed     Abstract available


  80. ZHOU S, Liu S, Tian G, Zhao L, et al
    KLK5 is associated with the radioresistance, aggression, and progression of cervical cancer.
    Gynecol Oncol. 2022 May 17. pii: S0090-8258(22)00309.
    PubMed     Abstract available


  81. WANG CC, Al-Rubaye R, Tran V, Montemorano L, et al
    Mechanical and oral antibiotic bowel preparation in ovarian cancer debulking: Are we lowering or just trading surgical complications?
    Gynecol Oncol. 2022 May 16. pii: S0090-8258(22)00307.
    PubMed     Abstract available


  82. HINCHCLIFF E, Westin SN, Herzog TJ
    State of the science: Contemporary front-line treatment of advanced ovarian cancer.
    Gynecol Oncol. 2022 May 16. pii: S0090-8258(22)00275.
    PubMed    


  83. ANGELES MA, Hernandez A, Perez-Benavente A, Cabarrou B, et al
    The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2022 May 11. pii: S0090-8258(22)00278.
    PubMed     Abstract available


  84. GUIDA F, Dioun S, Fagotti A, Melamed A, et al
    Role of tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2022 May 9. pii: S0090-8258(22)00218.
    PubMed     Abstract available


  85. MCKINNISH TR, Greenwade MM, Wilkinson-Ryan I, Schwarz JK, et al
    Management and prognosis of cervical cancer patients treated with definitive radiation therapy who have partial metabolic response on post-therapy positron emission tomography.
    Gynecol Oncol. 2022 May 7. pii: S0090-8258(22)00259.
    PubMed     Abstract available


  86. DEMARI JA, Boyles GP, Barrington DA, Audrey Busho BS, et al
    Less is more: Abdominal closure protocol does not reduce surgical site infection after hysterectomy.
    Gynecol Oncol. 2022 May 4. pii: S0090-8258(22)00261.
    PubMed     Abstract available


  87. STENZEL AE, Thomaier L, Jewett PI, Dona AC, et al
    Interactions between physical activity and type of cancer treatment received on associations with psychosocial outcomes among gynecologic cancer survivors.
    Gynecol Oncol. 2022 May 4. pii: S0090-8258(22)00260.
    PubMed     Abstract available


  88. RONSINI C, Kohler C, De Franciscis P, La Verde M, et al
    Laparo-assisted vaginal radical hysterectomy as a safe option for Minimal Invasive Surgery in early stage cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 May 2. pii: S0090-8258(22)00251.
    PubMed     Abstract available


  89. JAMIESON A, Thompson EF, Huvila J, Leung S, et al
    Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases.
    Gynecol Oncol. 2022;165:376-384.
    PubMed     Abstract available


  90. MAXWELL GL, Secord AA, Powell MA
    The ProMisE of uniform care for endometrial cancer patients.
    Gynecol Oncol. 2022;165:199-200.
    PubMed    


  91. KIM SK, Ursell P, Coleman RL, Monk BJ, et al
    Mitigation and management strategies for ocular events associated with tisotumab vedotin.
    Gynecol Oncol. 2022;165:385-392.
    PubMed     Abstract available


    April 2022
  92. THOMAS RJ, Provenzano D, Goyal S, Loew M, et al
    Trends in guideline-adherent chemoradiation therapy for locally advanced cervical cancer before and after the affordable care act.
    Gynecol Oncol. 2022 Apr 28. pii: S0090-8258(22)00256.
    PubMed     Abstract available


  93. JACKSON CG, Moore KN, Cantrell L, Erickson BK, et al
    A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.
    Gynecol Oncol. 2022 Apr 28. pii: S0090-8258(22)00257.
    PubMed     Abstract available


  94. WILHITE AM, Baca Y, Xiu J, Paladugu R, et al
    Molecular profiles of endometrial cancer tumors among Black patients.
    Gynecol Oncol. 2022 Apr 27. pii: S0090-8258(22)00255.
    PubMed     Abstract available


  95. XU JY, Chen JN, Lei J, Hu M, et al
    Local treatment improves survival in patients with stage IVB cervical cancer.
    Gynecol Oncol. 2022 Apr 27. pii: S0090-8258(22)00254.
    PubMed     Abstract available


  96. TANIGAWA T, Takeshima N, Ishikawa H, Nishio S, et al
    Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079).
    Gynecol Oncol. 2022 Apr 26. pii: S0090-8258(22)00252.
    PubMed     Abstract available


  97. KARPEL HC, Chern JY, Smith J M, Smith A J, et al
    Utility of germline multi-gene panel testing in patients with endometrial cancer.
    Gynecol Oncol. 2022 Apr 25. pii: S0090-8258(22)00216.
    PubMed     Abstract available


  98. FU Z, Taylor S, Modugno F
    Lifetime ovulations and epithelial ovarian cancer risk and survival: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Apr 23. pii: S0090-8258(22)00214.
    PubMed     Abstract available


  99. WANG D, Jia S, Jia C, Cao D, et al
    Oncological and reproductive outcomes after fertility-sparing surgery in patients with seromucinous borderline ovarian tumor: Results of a large retrospective study.
    Gynecol Oncol. 2022 Apr 22. pii: S0090-8258(22)00215.
    PubMed     Abstract available


  100. MA X, Ren X, Ma F, Cai S, et al
    Volumetric apparent diffusion coefficient (ADC) histogram metrics as imaging biomarkers for pretreatment predicting response to fertility-sparing treatment in patients with endometrial cancer.
    Gynecol Oncol. 2022 Apr 22. pii: S0090-8258(22)00249.
    PubMed     Abstract available


  101. BARRINGTON DA, Fox B, Meade C, Quick A, et al
    Does the addition of radiation improve survival compared to chemotherapy alone in women with stage IV endometrial carcinoma? Analysis of the NCDB and SEER databases.
    Gynecol Oncol. 2022 Apr 22. pii: S0090-8258(22)00248.
    PubMed     Abstract available


  102. POTHURI B, Eskander RN, Randall LM, O'Malley DM, et al
    Practice changing cervical cancer clinical trials.
    Gynecol Oncol. 2022 Apr 20. pii: S0090-8258(22)00175.
    PubMed    


  103. JOOYA ND, Ciccone MA, Brunette LL, Pham HQ, et al
    Population-level uptake of neoadjuvant chemotherapy for stage IVB endometrial cancer.
    Gynecol Oncol. 2022 Apr 19. pii: S0090-8258(22)00203.
    PubMed     Abstract available


  104. LUHRS O, Bollino M, Ekdahl L, Lonnerfors C, et al
    Similar distribution of pelvic sentinel lymph nodes and nodal metastases in cervical and endometrial cancer. A prospective study based on lymphatic anatomy.
    Gynecol Oncol. 2022 Apr 15. pii: S0090-8258(22)00209.
    PubMed     Abstract available


  105. COUGHLIN SS, Datta B, Guha A, Wang X, et al
    Cardiovascular conditions and obesity among gynecologic cancer survivors: Results from the 2020 behavioral risk factor surveillance system survey.
    Gynecol Oncol. 2022 Apr 15. pii: S0090-8258(22)00207.
    PubMed     Abstract available


  106. BARRINGTON DA, Riedinger C, Haight PJ, Tubbs C, et al
    Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2022 Apr 11. pii: S0090-8258(22)00213.
    PubMed     Abstract available


  107. LOF P, Retel VP, Algera MD, van Gent MDJM, et al
    Clinical implementation of routine diagnostic laparoscopy to guide initial treatment in patients with advanced-stage epithelial ovarian cancer in Dutch clinical practice: Evaluation of support and a budget impact analysis.
    Gynecol Oncol. 2022 Apr 9. pii: S0090-8258(22)00210.
    PubMed     Abstract available


  108. SAPIENZA LG, Thomas JJ, Showalter TN, Echeverria AE, et al
    Endoscopic assessment of radiological stage IVA cervical cancer: A bivariate meta-analysis supporting an evidence-based staging algorithm proposal.
    Gynecol Oncol. 2022 Apr 8. pii: S0090-8258(22)00208.
    PubMed     Abstract available


  109. CHAMBERS LM, Chalif J, Vargas R
    Analysis of patient experiences with gestational trophoblastic neoplasia reported on Instagram social media.
    Gynecol Oncol. 2022 Apr 8. pii: S0090-8258(22)00211.
    PubMed     Abstract available


  110. SON J, George GC, Nardo M, Krause KJ, et al
    Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Apr 7. pii: S0090-8258(22)00195.
    PubMed     Abstract available


  111. GERSEKOWSKI K, Delahunty R, Alsop K, Goode EL, et al
    Germline BRCA variants, lifestyle and ovarian cancer survival.
    Gynecol Oncol. 2022 Apr 7. pii: S0090-8258(22)00202.
    PubMed     Abstract available


  112. SAND FL, Frederiksen K, Kjaer SK
    Risk of recurrent disease following conization of cervical intraepithelial neoplasia grade 3 according to post-conization HPV status and surgical margins.
    Gynecol Oncol. 2022 Apr 7. pii: S0090-8258(22)00197.
    PubMed     Abstract available


  113. NORPPA N, Staff S, Helminen M, Auranen A, et al
    Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: Results from a tertiary referral center.
    Gynecol Oncol. 2022 Apr 6. pii: S0090-8258(22)00205.
    PubMed     Abstract available


  114. BIZZARRI N, Marchetti C, Conte C, Loverro M, et al
    The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery.
    Gynecol Oncol. 2022 Apr 6. pii: S0090-8258(22)00206.
    PubMed     Abstract available


  115. SALVO G, Jhingran A, Ramalingam P, Legarreta AF, et al
    Definitive pelvic radiation therapy improves survival in stage IVB neuroendocrine cervical carcinoma: A NeCTuR study.
    Gynecol Oncol. 2022 Apr 5. pii: S0090-8258(22)00204.
    PubMed     Abstract available


  116. HENNO S, Jeanne C, Rouge TM, Genestie C, et al
    Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG).
    Gynecol Oncol. 2022 Apr 4. pii: S0090-8258(22)00201.
    PubMed     Abstract available


  117. POLTERAUER S, Reich O, Widschwendter A, Hadjari L, et al
    Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: Multicenter, randomized controlled trial.
    Gynecol Oncol. 2022;165:23-29.
    PubMed     Abstract available


  118. PARPEX G, Bucau M, Estevez JP, Raimond E, et al
    Impact of vulvar reconstruction on the accuracy of a nomogram for predicting local recurrence after surgery for vulvar cancer.
    Gynecol Oncol. 2022;165:143-148.
    PubMed     Abstract available


  119. RAMOS MM, Maesta I, de Araujo Costa RA, Mazeto GMFS, et al
    Clinical characteristics and thyroid function in complete hydatidiform mole complicated by hyperthyroidism.
    Gynecol Oncol. 2022;165:137-142.
    PubMed     Abstract available


  120. LIAO X, Xia X, Su W, Yan H, et al
    Association of recurrent APOBEC3B alterations with the prognosis of gastric-type cervical adenocarcinoma.
    Gynecol Oncol. 2022;165:105-113.
    PubMed     Abstract available


  121. YAZDANFARD NW, Mikkelsen LH, Behrendt N, Fuglsang K, et al
    Vaginal melanoma in Denmark from 1980 to 2018: A population-based study based on genetic profile and survival.
    Gynecol Oncol. 2022;165:53-59.
    PubMed     Abstract available


  122. VAN DER PLOEG P, Uittenboogaard A, Bosch SL, van Diest PJ, et al
    Signal transduction pathway activity in high-grade serous carcinoma, its precursors and Fallopian tube epithelium.
    Gynecol Oncol. 2022;165:114-120.
    PubMed     Abstract available


  123. KASHOFER K, Regauer S, Reich O, Petru E, et al
    Driver gene mutations in micro-invasive cervical squamous cancers have no prognostic significance.
    Gynecol Oncol. 2022;165:121-128.
    PubMed     Abstract available


    March 2022
  124. SCHIFF JP, Mahmood M, Huang Y, Powell MA, et al
    The impact of tumor size and histology on local control when utilizing high-dose-rate interstitial brachytherapy for gynecologic malignancies.
    Gynecol Oncol. 2022 Mar 31. pii: S0090-8258(22)00199.
    PubMed     Abstract available


  125. MARINELLI LM, Kisiel JB, Slettedahl SW, Mahoney DW, et al
    Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility.
    Gynecol Oncol. 2022 Mar 31. pii: S0090-8258(22)00200.
    PubMed     Abstract available


  126. SIMILA-MAARALA J, Soovares P, Pasanen A, Ahvenainen T, et al
    TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma.
    Gynecol Oncol. 2022 Mar 31. pii: S0090-8258(22)00198.
    PubMed     Abstract available


  127. LIM H, In Shim J, Park SJ, Noh J, et al
    Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery.
    Gynecol Oncol. 2022 Mar 30. pii: S0090-8258(22)00196.
    PubMed     Abstract available


  128. MOHAMUD A, Hogdall C, Schnack T
    Prognostic value of the 2018 FIGO staging system for cervical cancer.
    Gynecol Oncol. 2022 Mar 25. pii: S0090-8258(22)00127.
    PubMed     Abstract available


  129. PERRONE E, De Felice F, Capasso I, Distefano E, et al
    The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method.
    Gynecol Oncol. 2022 Mar 24. pii: S0090-8258(22)00180.
    PubMed     Abstract available


  130. ZHANG L, Gu W, Zhang L, Miao R, et al
    The effects of a nurse-led couples intervention on marital quality of couples with gynecological cancer: A clinical randomized controlled trial.
    Gynecol Oncol. 2022 Mar 23. pii: S0090-8258(22)00181.
    PubMed     Abstract available


  131. STELTEN S, van Lonkhuijzen LRCW, Hartman YAW, van Driel WJ, et al
    Experiences, adherence and satisfaction with a combined exercise and dietary intervention for patients with ovarian cancer undergoing chemotherapy: A mixed-methods study.
    Gynecol Oncol. 2022 Mar 22. pii: S0090-8258(22)00182.
    PubMed     Abstract available


  132. DAIX M, Martinez Gomez C, Angeles MA, Tock S, et al
    Extended pelvic resection for gynecological malignancies: A review of out-of-the-box surgery.
    Gynecol Oncol. 2022 Mar 21. pii: S0090-8258(22)00174.
    PubMed     Abstract available


  133. VARGIU V, Rosati A, Capozzi VA, Sozzi G, et al
    Impact of Obesity on Sentinel Lymph Node Mapping in Patients with apparent Early-Stage Endometrial Cancer: The ObeLyX study.
    Gynecol Oncol. 2022 Mar 18. pii: S0090-8258(22)00173.
    PubMed     Abstract available


  134. ARGENTA PA, Mattson J, Rivard CL, Luther E, et al
    Robot-assisted versus laparoscopic minimally invasive surgery for the treatment of stage I endometrial cancer.
    Gynecol Oncol. 2022 Mar 18. pii: S0090-8258(22)00178.
    PubMed     Abstract available


  135. KULKARNI A, Sun G, Manuppelli S, Mendez H, et al
    Sexual health and function among patients receiving systemic therapy for primary gynecologic cancers.
    Gynecol Oncol. 2022 Mar 17. pii: S0090-8258(22)00179.
    PubMed     Abstract available


  136. SHIM JI, Ryu JY, Jeong SY, Cho YJ, et al
    Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer.
    Gynecol Oncol. 2022 Mar 16. pii: S0090-8258(22)00176.
    PubMed     Abstract available


  137. HACK AP, Zweemer RP, Jonges TN, van der Leij F, et al
    Prognostic impact of waiting time between diagnosis and treatment in patients with cervical cancer: A nationwide population-based study.
    Gynecol Oncol. 2022 Mar 14. pii: S0090-8258(22)00177.
    PubMed     Abstract available


  138. MOUKARZEL LA, Ferrando L, Dopeso H, Stylianou A, et al
    Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues.
    Gynecol Oncol. 2022 Mar 12. pii: S0090-8258(22)00141.
    PubMed     Abstract available


  139. POST CCB, Westermann AM, Boere IA, Witteveen PO, et al
    Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial).
    Gynecol Oncol. 2022 Mar 11. pii: S0090-8258(22)00145.
    PubMed     Abstract available


  140. SIEGENTHALER F, Lindemann K, Epstein E, Rau TT, et al
    Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification.
    Gynecol Oncol. 2022 Mar 8. pii: S0090-8258(22)00143.
    PubMed     Abstract available


  141. HAWKINS GM, Burkett WC, McCoy AN, Nichols HB, et al
    Differences in the microbial profiles of early stage endometrial cancers between Black and White women.
    Gynecol Oncol. 2022 Mar 8. pii: S0090-8258(22)00142.
    PubMed     Abstract available


  142. KIM J, Noh JJ, Lee TK, Kim SI, et al
    Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea.
    Gynecol Oncol. 2022 Mar 8. pii: S0090-8258(22)00140.
    PubMed     Abstract available


  143. MATSUO K, Klar M, Khetan VU, Vallejo A, et al
    Uptake in sentinel lymph node biopsy for endometrial cancer with T3 classification.
    Gynecol Oncol. 2022 Mar 7. pii: S0090-8258(22)00144.
    PubMed     Abstract available


  144. CHALIF J, Yao M, Gruner M, Kuznicki M, et al
    Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancer.
    Gynecol Oncol. 2022 Mar 7. pii: S0090-8258(22)00065.
    PubMed     Abstract available


  145. SCHNARR KL, Seow H, Pond GR, Helpman L, et al
    The impact of preoperative imaging on wait times, surgical approach and overall survival in endometrioid endometrial cancers.
    Gynecol Oncol. 2022 Mar 2. pii: S0090-8258(22)00129.
    PubMed     Abstract available


  146. LEITAO MM JR
    The end of routine lymphadenectomy for the treatment of cervical cancer is rapidly approaching.
    Gynecol Oncol. 2022;164:461-462.
    PubMed    


  147. JAMIESON A, Huvila J, Thompson EF, Leung S, et al
    Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification.
    Gynecol Oncol. 2022 Mar 1. pii: S0090-8258(22)00085.
    PubMed     Abstract available


  148. BRUNETTE LL, Khetan VU, Deshpande RR, Nusbaum DJ, et al
    Population-level trends and outcomes of sentinel lymph node biopsy in vulvar cancer surgery in the United States.
    Gynecol Oncol. 2022;164:651-657.
    PubMed     Abstract available


  149. SCHLEISS-ANDREASSEN JL, Kristensen E, Froding LP, Staehr E, et al
    Assessment of recurrence rate and risk factors of relapse in stage in IA vulvar carcinoma.
    Gynecol Oncol. 2022;164:543-549.
    PubMed     Abstract available


    February 2022
  150. GOINS EC, Weber JM, Truong T, Moss HA, et al
    Malnutrition as a risk factor for post-operative morbidity in gynecologic cancer: Analysis using a national surgical outcomes database.
    Gynecol Oncol. 2022 Feb 28. pii: S0090-8258(22)00069.
    PubMed     Abstract available


  151. PH M, Maulard A, Scherier S, Sanson C, et al
    Oncologic results of fertility sparing surgery of cervical cancer: An updated systematic review.
    Gynecol Oncol. 2022 Feb 28. pii: S0090-8258(22)00051.
    PubMed     Abstract available


  152. MATSUO K, Khetan VU, Brunette LL, Jooya ND, et al
    Characterizing isolated tumor cells in regional lymph nodes of early endometrial cancer.
    Gynecol Oncol. 2022 Feb 26. pii: S0090-8258(22)00125.
    PubMed     Abstract available


  153. ZAMMARRELLI WA 3RD, Greenman M, Rios-Doria E, Miller K, et al
    Sentinel lymph node biopsy alone compared to systematic lymphadenectomy in patients with uterine carcinosarcoma.
    Gynecol Oncol. 2022 Feb 26. pii: S0090-8258(22)00122.
    PubMed     Abstract available


  154. FALCONE F, Malzoni M, Carnelli M, Cormio G, et al
    Fertility-sparing treatment for serous borderline ovarian tumors with extra-ovarian invasive implants: Analysis from the MITO14 study database.
    Gynecol Oncol. 2022 Feb 26. pii: S0090-8258(22)00128.
    PubMed     Abstract available


  155. MATSUO K, Chen L, Guo XM, Roman LD, et al
    Hormonal therapy or chemotherapy for early-stage, low-grade endometrial cancer with malignant peritoneal cytology: A comparative effectiveness study.
    Gynecol Oncol. 2022 Feb 25. pii: S0090-8258(22)00126.
    PubMed     Abstract available


  156. KOBAYASHI E, Nakatani E, Tanaka T, Yosuke K, et al
    Surgical skill and oncological outcome of laparoscopic radical hysterectomy: JGOG1081s-A1, an ancillary analysis of the Japanese Gynecologic Oncology Group Study JGOG1081.
    Gynecol Oncol. 2022 Feb 24. pii: S0090-8258(22)00089.
    PubMed     Abstract available


  157. MANYAM M, Stephens AJ, Kennard JA, LeBlanc J, et al
    Corrigendum to "A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer" [Gynecologic Oncology 163 (2021) 481-489].
    Gynecol Oncol. 2022 Feb 23. pii: S0090-8258(22)00124.
    PubMed    


  158. BAETEN IGT, Hoogendam JP, Jonges GN, Jurgenliemk-Schulz IM, et al
    Value of routine cytokeratin immunohistochemistry in detecting low volume disease in cervical cancer.
    Gynecol Oncol. 2022 Feb 23. pii: S0090-8258(22)00121.
    PubMed     Abstract available


  159. ALGERA MD, van Driel WJ, Slangen BFM, Kruitwagen RFPM, et al
    Impact of the COVID-19-pandemic on patients with gynecological malignancies undergoing surgery: A Dutch population-based study using data from the 'Dutch Gynecological Oncology Audit'.
    Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00123.
    PubMed     Abstract available


  160. KIM YN, Kim JC, Chung YS, Park J, et al
    Incidence of postoperative thrombotic events in ovarian cancer patients with a de-escalated prophylactic strategy: A retrospective cohort study.
    Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00091.
    PubMed     Abstract available


  161. ANDERSON EM, Luu M, Lu DJ, Chung EM, et al
    Pathologic primary tumor factors associated with risk of lymph node involvement in patients with non-endometrioid endometrial cancer.
    Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00024.
    PubMed     Abstract available


  162. LAFARGUE CJ, Handley KF, Fleming ND, Nick AM, et al
    Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer.
    Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00090.
    PubMed     Abstract available


  163. HUANG Y, Hou JY, Melamed A, St Clair CM, et al
    Pathologic characteristics, patterns of care, and outcomes of Asian-Americans and Pacific islanders with uterine cancer.
    Gynecol Oncol. 2022 Feb 16. pii: S0090-8258(22)00088.
    PubMed     Abstract available


  164. VANDERSTICHELE A, Loverix L, Busschaert P, Van Nieuwenhuysen E, et al
    Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.
    Gynecol Oncol. 2022 Feb 14. pii: S0090-8258(22)00073.
    PubMed     Abstract available


  165. DHOLAKIA J, Liang MI, Aviki EM
    Missing the target: The oncology care model treatment pricing scheme is prohibitively reductive for gynecologic malignancies.
    Gynecol Oncol. 2022 Feb 12. pii: S0090-8258(22)00087.
    PubMed    


  166. PARK J, Kim SI, Jeong SY, Kim Y, et al
    Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
    Gynecol Oncol. 2022 Feb 10. pii: S0090-8258(22)00086.
    PubMed     Abstract available


  167. YAHATA H, Kodama K, Okugawa K, Hachisuga K, et al
    Long-term follow up after sentinel node biopsy alone for early-stage cervical cancer.
    Gynecol Oncol. 2022 Feb 9. pii: S0090-8258(22)00070.
    PubMed     Abstract available


  168. KRAUS EJ, Nicosia B, Shalowitz DI
    A qualitative study of patients' attitudes towards telemedicine for gynecologic cancer care.
    Gynecol Oncol. 2022 Feb 8. pii: S0090-8258(22)00074.
    PubMed     Abstract available


  169. WAGAR MK, Mojdehbakhsh RP, Godecker A, Rice LW, et al
    Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers.
    Gynecol Oncol. 2022 Feb 7. pii: S0090-8258(22)00071.
    PubMed     Abstract available


  170. LEMON LS, Orr B, Modugno F, Buckanovich RJ, et al
    Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer?
    Gynecol Oncol. 2022 Feb 6. pii: S0090-8258(22)00049.
    PubMed     Abstract available


  171. JOLY F, Fabbro M, Follana P, Lequesne J, et al
    A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
    Gynecol Oncol. 2022 Feb 2. pii: S0090-8258(22)00048.
    PubMed     Abstract available


  172. SWIFT BE, Tigert M, Nica A, Covens A, et al
    The accuracy of intraoperative frozen section examination of sentinel lymph nodes in squamous cell cancer of the vulva.
    Gynecol Oncol. 2022;164:393-397.
    PubMed     Abstract available


  173. SHIN DW, Bae J, Ha J, Lee WM, et al
    Trends in incidence and survival of patients with vulvar cancer in an Asian country: Analysis of the Korean Central Cancer Registry 1999-2018.
    Gynecol Oncol. 2022;164:386-392.
    PubMed     Abstract available


    January 2022
  174. TRILLSCH F, Mahner S, Ataseven B, Asher R, et al
    Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
    Gynecol Oncol. 2022 Jan 31. pii: S0090-8258(22)00050.
    PubMed     Abstract available


  175. LICHTER KE, Levinson K, Hammer A, Lippitt MH, et al
    Understanding cervical cancer after the age of routine screening: Characteristics of cases, treatment, and survival in the United States.
    Gynecol Oncol. 2022 Jan 31. pii: S0090-8258(22)00025.
    PubMed     Abstract available


  176. RAIMONDO D, Raffone A, Zakhari A, Maletta M, et al
    The impact of hysterectomy on oncological outcomes in patients with borderline ovarian tumors: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Jan 25. pii: S0090-8258(22)00046.
    PubMed     Abstract available


  177. WU X, Keller EJ, Rabei R, Rockwell H, et al
    Cost-effectiveness of tunneled peritoneal catheters versus repeat paracenteses for recurrent ascites in gynecologic malignancies.
    Gynecol Oncol. 2022 Jan 24. pii: S0090-8258(22)00019.
    PubMed     Abstract available


  178. RAFFONE A, Travaglino A, Raimondo D, Neola D, et al
    Lymphovascular space invasion in endometrial carcinoma: A prognostic factor independent from molecular signature.
    Gynecol Oncol. 2022 Jan 22. pii: S0090-8258(22)00020.
    PubMed     Abstract available


  179. WATSON CH, Monuszko K, Freeman S, Kurtovic K, et al
    Reducing non-surgical readmissions on a gynecologic oncology service.
    Gynecol Oncol. 2022 Jan 22. pii: S0090-8258(22)00005.
    PubMed     Abstract available


  180. LEON-CASTILLO A, Horeweg N, Peters EEM, Rutten T, et al
    Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
    Gynecol Oncol. 2022 Jan 22. pii: S0090-8258(22)00007.
    PubMed     Abstract available


  181. COLOMBO N, Tomao F, Benedetti Panici P, Nicoletto MO, et al
    Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00023.
    PubMed     Abstract available


  182. XIA YY, Gronwald J, Karlan B, Lubinski J, et al
    Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00022.
    PubMed     Abstract available


  183. BOGANI G, Ray-Coquard I, Concin N, Ngoi NYL, et al
    Clear cell carcinoma of the endometrium.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00021.
    PubMed     Abstract available


  184. SLOMOVITZ BM, Filiaci VL, Walker JL, Taub MC, et al
    A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(21)01699.
    PubMed     Abstract available


  185. BOUCHARD-FORTIER G, Gien LT, Sutradhar R, Chan WC, et al
    Impact of care by gynecologic oncologists on primary ovarian cancer survival: A population-based study.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00004.
    PubMed     Abstract available


  186. POVEDA A, Lheureux S, Colombo N, Cibula D, et al
    Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(21)01693.
    PubMed     Abstract available


  187. ZHANG J, Yu S, Li Q, Wang Q, et al
    Increased co-expression of MEST and BRCA1 is associated with worse prognosis and immune infiltration in ovarian cancer.
    Gynecol Oncol. 2022 Jan 15. pii: S0090-8258(22)00018.
    PubMed     Abstract available


  188. FIEGL H, Hagenbuchner J, Kyvelidou C, Seeber B, et al
    Dubious effects of methadone as an "anticancer" drug on ovarian cancer cell-lines and patient-derived tumor-spheroids.
    Gynecol Oncol. 2022 Jan 12. pii: S0090-8258(22)00009.
    PubMed     Abstract available


  189. BEINSE G, Le Frere Belda MA, Just PA, Bekmezian N, et al
    Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer.
    Gynecol Oncol. 2022 Jan 12. pii: S0090-8258(22)00006.
    PubMed     Abstract available


  190. YAN L, Liu Y, Zhang J, Chen X, et al
    In vivo and in vitro study of the potential hazards of surgical smoke during cervical cancer treatment with an ultrasonic scalpel.
    Gynecol Oncol. 2022 Jan 12. pii: S0090-8258(22)00008.
    PubMed     Abstract available


  191. ALTIN D, Taskin S, Ortac F, Tokgozoglu N, et al
    Diagnostic accuracy of sentinel node biopsy in non-endometrioid, high-grade and/or deep myoinvasive endometrial cancer: A Turkish gynecologic oncology group study (TRSGO-SLN-006).
    Gynecol Oncol. 2022 Jan 12. pii: S0090-8258(22)00003.
    PubMed     Abstract available


  192. MUSA FB, Brouwer E, Ting J, Schwartz NRM, et al
    Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer.
    Gynecol Oncol. 2022 Jan 11. pii: S0090-8258(21)01696.
    PubMed     Abstract available


  193. REID HW, Broadwater G, Montes de Oca MK, Selvan B, et al
    Distress screening in endometrial cancer leads to disparity in referral to support services.
    Gynecol Oncol. 2022 Jan 8. pii: S0090-8258(22)00001.
    PubMed     Abstract available


  194. TEMKIN SM, Chapman-Davis E, Nair N, Cohn DE, et al
    Creating work environments where people of all genders in gynecologic oncology can thrive: An SGO evidence-based review.
    Gynecol Oncol. 2022 Jan 6. pii: S0090-8258(21)01700.
    PubMed     Abstract available


  195. AMPOFO AG, Boyes AW, Khumalo PG, Mackenzie L, et al
    Improving knowledge, attitudes, and uptake of cervical cancer prevention among female students: A systematic review and meta-analysis of school-based health education.
    Gynecol Oncol. 2022 Jan 5. pii: S0090-8258(21)01680.
    PubMed     Abstract available


  196. WEINMANN S, Phillips S, Sweet K, Cosgrove CM, et al
    Hospital-based ovarian cancer patient traceback program results in minimal genetic testing uptake.
    Gynecol Oncol. 2022 Jan 5. pii: S0090-8258(21)01695.
    PubMed     Abstract available


  197. LIN DI, Fine A, Danziger NA, Huang RSP, et al
    Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.
    Gynecol Oncol. 2022 Jan 5. pii: S0090-8258(21)01698.
    PubMed     Abstract available


  198. WANG J, Dong J, Zhou Y, Wang K, et al
    Performance of human papillomavirus (HPV) mRNA testing and HPV 16 and 18/45 genotyping combined with age stratification in the triaging of women with ASC-US cytology.
    Gynecol Oncol. 2022 Jan 4. pii: S0090-8258(21)01701.
    PubMed     Abstract available


  199. SHALOWITZ DI, DeMari JA
    Defining the essential role of the gynecologic oncologist in rural ovarian cancer care delivery.
    Gynecol Oncol. 2022;164:1-2.
    PubMed    


  200. WOELBER L, Prieske K, Eulenburg CZ, Corradini S, et al
    Adjuvant radiotherapy and local recurrence in vulvar cancer - a subset analysis of the AGO-CaRE-1 study.
    Gynecol Oncol. 2022;164:68-75.
    PubMed     Abstract available


  201. BORCINOVA M, Ragosch V, Jarkovsky J, Bajsova S, et al
    Challenges in lower limb lymphoedema assessment based on limb volume change: Lessons learnt from the SENTIX prospective multicentre study.
    Gynecol Oncol. 2022;164:76-84.
    PubMed     Abstract available


    December 2021
  202. EKDAHL L, Paraghamian S, Eoh KJ, Thumuluru KM, et al
    Long term oncologic and reproductive outcomes after robot-assisted radical trachelectomy for early-stage cervical cancer. An international multicenter study.
    Gynecol Oncol. 2021 Dec 31. pii: S0090-8258(21)01697.
    PubMed     Abstract available


  203. CORRIGAN KL, Yoder A, De B, Lin L, et al
    Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis.
    Gynecol Oncol. 2021 Dec 30. pii: S0090-8258(21)01690.
    PubMed     Abstract available


  204. SPONHOLTZ SE, Ezendam NPM, de Rooij BH, Parner E, et al
    SENTIREC - The sentinel node mapping in women with cervical cancer study - Patient-reported early lymphedema and its impact on quality of life.
    Gynecol Oncol. 2021 Dec 29. pii: S0090-8258(21)01692.
    PubMed     Abstract available


  205. KIM SI, Choi BR, Kim HS, Chung HH, et al
    Cervical conization before primary radical hysterectomy has a protective effect on disease recurrence in early cervical cancer: A two-center matched cohort study according to surgical approach.
    Gynecol Oncol. 2021 Dec 27. pii: S0090-8258(21)01691.
    PubMed     Abstract available


  206. LIGHTFOOT MDS, Felix AS, Bishop EE, Henderson AP, et al
    Who will be readmitted? Evaluation of the laparoscopic hysterectomy readmission score in a gynecologic oncology population undergoing robotic-assisted hysterectomy.
    Gynecol Oncol. 2021 Dec 27. pii: S0090-8258(21)01636.
    PubMed     Abstract available


  207. THELISSEN AAB, Jurgenliemk-Schulz IM, van der Leij F, Peters M, et al
    Upstaging by para-aortic lymph node dissection in patients with locally advanced cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Dec 27. pii: S0090-8258(21)01694.
    PubMed     Abstract available


  208. BEESLEY VL, Ross TL, King MT, Campbell R, et al
    Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns).
    Gynecol Oncol. 2021 Dec 23. pii: S0090-8258(21)01632.
    PubMed     Abstract available


  209. REIJNTJES B, van Suijlichem M, Woolderink JM, Bongers MY, et al
    Recurrence and survival after laparoscopy versus laparotomy without lymphadenectomy in early-stage endometrial cancer: Long-term outcomes of a randomised trial.
    Gynecol Oncol. 2021 Dec 23. pii: S0090-8258(21)01676.
    PubMed     Abstract available


  210. CIBULA D, Dostalek L, Jarkovsky J, Mom CH, et al
    Post-recurrence survival in patients with cervical cancer.
    Gynecol Oncol. 2021 Dec 23. pii: S0090-8258(21)01675.
    PubMed     Abstract available


  211. PHILP L, Alimena S, Ferris W, Saini A, et al
    Patient reported outcomes after risk-reducing surgery in patients at increased risk of ovarian cancer.
    Gynecol Oncol. 2021 Dec 22. pii: S0090-8258(21)01674.
    PubMed     Abstract available


  212. HARTER P, Mouret-Reynier MA, Pignata S, Cropet C, et al
    Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
    Gynecol Oncol. 2021 Dec 21. pii: S0090-8258(21)01673.
    PubMed     Abstract available


  213. MONK BJ, Smith G, Lima J, Long GH, et al
    Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records.
    Gynecol Oncol. 2021 Dec 21. pii: S0090-8258(21)01634.
    PubMed     Abstract available


  214. KO EM, Bekelman JE, Hicks-Courant K, Brensinger CM, et al
    Association of gynecologic oncology versus medical oncology specialty with survival, utilization, and spending for treatment of gynecologic cancers.
    Gynecol Oncol. 2021 Dec 20. pii: S0090-8258(21)01627.
    PubMed     Abstract available


  215. GUANI B, Mahiou K, Crestani A, Cibula D, et al
    Clinical impact of low-volume lymph node metastases in early-stage cervical cancer: A comprehensive meta-analysis.
    Gynecol Oncol. 2021 Dec 20. pii: S0090-8258(21)01672.
    PubMed     Abstract available


  216. AGHAJANIAN C, Swisher EM, Okamoto A, Steffensen KD, et al
    Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
    Gynecol Oncol. 2021 Dec 17. pii: S0090-8258(21)01638.
    PubMed     Abstract available


  217. HA HI, Park EY, Eoh KJ, Lee YJ, et al
    Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer.
    Gynecol Oncol. 2021 Dec 16. pii: S0090-8258(21)01639.
    PubMed     Abstract available


  218. DAVIDSON BA, Puechl AM, Watson CH, Lim S, et al
    Promoting timely goals of care conversations between gynecologic cancer patients at high-risk of death and their providers.
    Gynecol Oncol. 2021 Dec 15. pii: S0090-8258(21)01635.
    PubMed     Abstract available


  219. SWIFT BE, Maeda A, Bouchard-Fortier G
    Low incidence of venous thromboembolism after gynecologic oncology surgery: Who is at greatest risk?
    Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01637.
    PubMed     Abstract available


  220. SHI Y, Chen J, Shi B, Liu A, et al
    Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
    Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01633.
    PubMed     Abstract available


  221. ZHOU ZN, Chen L, Melamed A, St Clair CM, et al
    Adoption of minimally invasive surgery after neoadjuvant chemotherapy in women with metastatic uterine cancer.
    Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01631.
    PubMed     Abstract available


  222. DEBOER RJ, Umutoni V, Bazzett-Matabele L, Katznelson E, et al
    Cervical cancer treatment in Rwanda: Resource-driven adaptations, quality indicators, and patient outcomes.
    Gynecol Oncol. 2021 Dec 13. pii: S0090-8258(21)01628.
    PubMed     Abstract available


  223. SWISHER EM, Aghajanian C, O'Malley DM, Fleming GF, et al
    Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
    Gynecol Oncol. 2021 Dec 11. pii: S0090-8258(21)01630.
    PubMed     Abstract available


  224. MATULONIS UA, Huang HQ, Filiaci VL, Randall M, et al
    Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.
    Gynecol Oncol. 2021 Dec 10. pii: S0090-8258(21)01625.
    PubMed     Abstract available


  225. NICA A, Sutradhar R, Kupets R, Covens A, et al
    Pre-operative wait times in high-grade non-endometrioid endometrial cancer: Do surgical delays impact patient survival?
    Gynecol Oncol. 2021 Dec 9. pii: S0090-8258(21)01621.
    PubMed     Abstract available


  226. LARA OD, Smith M, Wang Y, O'Cearbhaill RE, et al
    COVID-19 outcomes of patients with gynecologic cancer in New York City: An updated analysis from the initial surge of the pandemic.
    Gynecol Oncol. 2021 Dec 7. pii: S0090-8258(21)01629.
    PubMed     Abstract available


  227. KORENAGA TK, Yoshida EJ, Pierson W, Chang J, et al
    Better late than never: Brachytherapy is more important than timing in treatment of locally advanced cervical cancer.
    Gynecol Oncol. 2021 Dec 2. pii: S0090-8258(21)01608.
    PubMed     Abstract available


  228. WEI JJ
    Linking altered microRNA expression to racial disparities in uterine serous carcinoma.
    Gynecol Oncol. 2021;163:446-447.
    PubMed    


  229. HODGSON DR, Brown JS, Dearden SP, Lai Z, et al
    Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.
    Gynecol Oncol. 2021;163:563-568.
    PubMed     Abstract available


    November 2021
  230. JOHN CS, Fong A, Alban R, Gillen J, et al
    Breast cancer surveillance following ovarian cancer in BRCA mutation carriers.
    Gynecol Oncol. 2021 Nov 30. pii: S0090-8258(21)01521.
    PubMed     Abstract available


  231. DOLL KM, Nguyen A, Alson JG
    A conceptual model of vulnerability to care delay among women at risk for endometrial cancer.
    Gynecol Oncol. 2021 Nov 30. pii: S0090-8258(21)01603.
    PubMed     Abstract available


  232. DUPONT NC, Enserro D, Brady MF, Moxley K, et al
    Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2021 Nov 29. pii: S0090-8258(21)01607.
    PubMed     Abstract available


  233. MANZOUR N, Nunez-Cordoba JM, Chiva L, Chacon E, et al
    Pattern of relapse in patients with stage IB1 cervical cancer after radical hysterectomy as primary treatment. Minimally invasive surgery vs. open approach. Systematic review and meta-analysis.
    Gynecol Oncol. 2021 Nov 27. pii: S0090-8258(21)01623.
    PubMed     Abstract available


  234. MOYA-ALARCON C, Gonzalez-Dominguez A, Ivanova-Markova Y, Gimeno-Ballester V, et al
    Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
    Gynecol Oncol. 2021 Nov 26. pii: S0090-8258(21)01604.
    PubMed     Abstract available


  235. CIANCI S, Fedele C, Vizzielli G, Pasciuto T, et al
    Surgical outcomes of diaphragmatic resection during cytoreductive surgery for advanced gynecological ovarian neoplasia: A randomized single center clinical trial - DRAGON.
    Gynecol Oncol. 2021 Nov 26. pii: S0090-8258(21)01605.
    PubMed     Abstract available


  236. ARYASOMAYAJULA C, Chanana A, Tandel M, Kwan L, et al
    The role of high-risk HPV testing in cervical cancer surveillance.
    Gynecol Oncol. 2021 Nov 23. pii: S0090-8258(21)01606.
    PubMed     Abstract available


  237. RASMUSSEN M, Lim K, Rambech E, Andersen MH, et al
    Corrigendum to "Lynch syndrome-associated epithelial ovarian cancer and its immunological profile" [Gynecologic Oncology 162 (2021) 686-693].
    Gynecol Oncol. 2021 Nov 19. pii: S0090-8258(21)01601.
    PubMed    


  238. NJOKU K, Ramchander NC, Wan YL, Barr CE, et al
    Pre-treatment inflammatory parameters predict survival from endometrial cancer: A prospective database analysis.
    Gynecol Oncol. 2021 Nov 18. pii: S0090-8258(21)01602.
    PubMed     Abstract available


  239. MATUSZEWSKA K, Ten Kortenaar S, Pereira M, Santry LA, et al
    Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer.
    Gynecol Oncol. 2021 Nov 16. pii: S0090-8258(21)01599.
    PubMed     Abstract available


  240. HUANG J, Deng Y, Boakye D, Tin MS, et al
    Global distribution, risk factors, and recent trends for cervical cancer: A worldwide country-level analysis.
    Gynecol Oncol. 2021 Nov 16. pii: S0090-8258(21)01598.
    PubMed     Abstract available


  241. LADBURY C, Li R, Shiao J, Liu J, et al
    Characterizing impact of positive lymph node number in endometrial cancer using machine-learning: A better prognostic indicator than FIGO staging?
    Gynecol Oncol. 2021 Nov 15. pii: S0090-8258(21)01600.
    PubMed     Abstract available


  242. MATTHEWS BJ, Qureshi MM, Fiascone SJ, Nitschmann CC, et al
    Racial disparities in non-recommendation of adjuvant chemotherapy in stage II-III ovarian cancer.
    Gynecol Oncol. 2021 Nov 13. pii: S0090-8258(21)01553.
    PubMed     Abstract available


  243. WEEKS KS, Lynch CF, West M, Carnahan R, et al
    Gynecologic oncologist impact on adjuvant chemotherapy care for stage II-IV ovarian cancer patients.
    Gynecol Oncol. 2021 Nov 11. pii: S0090-8258(21)01555.
    PubMed     Abstract available


  244. KHOJA L, Weber RP, Webb PM, Jordan SJ, et al
    Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association.
    Gynecol Oncol. 2021 Nov 11. pii: S0090-8258(21)01552.
    PubMed     Abstract available


  245. FABER MT, Horsbol TA, Baandrup L, Dalton SO, et al
    Trends in survival of epithelial ovarian/tubal cancer by histology and socioeconomic status in Denmark 1996-2017.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01554.
    PubMed     Abstract available


  246. PRAISS AM, Huang Y, St Clair CM, Melamed A, et al
    Long-term outcomes of vaginal hysterectomy for endometrial cancer.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01526.
    PubMed     Abstract available


  247. SISODIA RC, Alimena S, Ferris W, Saini A, et al
    Initial findings from a prospective, large scale patient reported outcomes program in patients with gynecologic malignancy.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01528.
    PubMed     Abstract available


  248. MANNING-GEIST BL, Gordhandas SB, Giri DD, Iasonos A, et al
    Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01551.
    PubMed     Abstract available


  249. ORELLANA TJ, Kim H, Beriwal S, Bhargava R, et al
    Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer.
    Gynecol Oncol. 2021 Nov 2. pii: S0090-8258(21)01515.
    PubMed     Abstract available


  250. MENG Y, Chu T, Lin S, Wu P, et al
    Clinicopathological characteristics and prognosis of cervical cancer with different histological types: A population-based cohort study.
    Gynecol Oncol. 2021 Nov 2. pii: S0090-8258(21)01451.
    PubMed     Abstract available


  251. ALHILLI MM, Arend RC
    International gynecologic cancer society (IGCS) 2021 meeting report.
    Gynecol Oncol. 2021 Nov 1. pii: S0090-8258(21)01548.
    PubMed    


  252. HINCHCLIFF EM, Westin SN
    Next generation sequencing for gynecologic malignancy: Promise and potential pitfalls.
    Gynecol Oncol. 2021;163:217-219.
    PubMed    


  253. SACCARDI C, Zovato S, Spagnol G, Bonaldo G, et al
    Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
    Gynecol Oncol. 2021;163:364-370.
    PubMed     Abstract available


    October 2021
  254. MATSUO K, Klar M, Khetan VU, Violette CJ, et al
    Sentinel lymph node biopsy for stage II endometrial cancer: Recent utilization and outcome in the United States.
    Gynecol Oncol. 2021 Oct 30. pii: S0090-8258(21)01529.
    PubMed     Abstract available


  255. ROCCONI RP, Wilhite AM, Schambeau L, Scalici J, et al
    A novel proteomic-based screening method for ovarian cancer using cervicovaginal fluids: A window into the abdomen.
    Gynecol Oncol. 2021 Oct 29. pii: S0090-8258(21)01527.
    PubMed     Abstract available


  256. CALO CA, Smith BQ, Dorayappan KDP, Saini U, et al
    Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound.
    Gynecol Oncol. 2021 Oct 29. pii: S0090-8258(21)01520.
    PubMed     Abstract available


  257. WARRING SK, Borah B, Moriarty J, Gullerud R, et al
    The cost of diagnosing endometrial cancer: Quantifying the healthcare cost of an abnormal uterine bleeding workup.
    Gynecol Oncol. 2021 Oct 27. pii: S0090-8258(21)01523.
    PubMed     Abstract available


  258. GOLDBERG RM, Kim SR, Fazelzad R, Li X, et al
    Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Oct 27. pii: S0090-8258(21)01524.
    PubMed     Abstract available


  259. EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al
    Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study.
    Gynecol Oncol. 2021 Oct 26. pii: S0090-8258(21)01525.
    PubMed     Abstract available


  260. CHARGARI C, Arbyn M, Leary A, Abu-Rustum NR, et al
    Increasing global accessibility to high-level treatments for cervical cancers.
    Gynecol Oncol. 2021 Oct 26. pii: S0090-8258(21)01517.
    PubMed     Abstract available


  261. SOOVARES P, Pasanen A, Simila-Maarala J, Butzow R, et al
    Clinical factors and biomarker profiles associated with patient outcome in endometrioid ovarian carcinoma - Emphasis on tumor grade.
    Gynecol Oncol. 2021 Oct 25. pii: S0090-8258(21)01522.
    PubMed     Abstract available


  262. WALTER A, Rocconi RP, Monk BJ, Herzog TJ, et al
    Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
    Gynecol Oncol. 2021 Oct 23. pii: S0090-8258(21)01422.
    PubMed     Abstract available


  263. WITJES VM, van Bommel MHD, Ligtenberg MJL, Vos JR, et al
    Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
    Gynecol Oncol. 2021 Oct 23. pii: S0090-8258(21)01516.
    PubMed     Abstract available


  264. BALAYA V, Guani B, Morice P, Querleu D, et al
    Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer: A post-hoc analysis of SENTICOL I and SENTICOL II cohorts.
    Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01518.
    PubMed     Abstract available


  265. SHIN W, Park SY, Seo SS, Lim MC, et al
    Predicting the risk of the distant recurrence of cervical cancer after concurrent chemoradiation: A validation study of the Korean Gynecologic Oncologic Group (KGOG)-1024 model.
    Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01514.
    PubMed     Abstract available


  266. TREDAN O, Provansal M, Abdeddaim C, Lardy-Cleaud A, et al
    Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
    Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01402.
    PubMed     Abstract available


  267. GUDGEON JM, Wallentine JC, Bonham EM, McLaughlin HD, et al
    Determination of test performance of two contemporary screening tests for Lynch syndrome in endometrial cancer: A clinical trial.
    Gynecol Oncol. 2021 Oct 21. pii: S0090-8258(21)01401.
    PubMed     Abstract available


  268. HE WQ, Li C
    Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends.
    Gynecol Oncol. 2021 Oct 20. pii: S0090-8258(21)01519.
    PubMed     Abstract available


  269. HARRISON R, Zighelboim I, Cloven NG, Marcus JZ, et al
    Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement.
    Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01452.
    PubMed    


  270. HOROWITZ NS, Eskander RN, Adelman MR, Burke W, et al
    Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation.
    Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01421.
    PubMed    


  271. MANYAM M, Stephens AJ, Kennard JA, LeBlanc J, et al
    A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer.
    Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01513.
    PubMed     Abstract available


  272. MARTIN A, Wells A, Anderson ML, Chern JY, et al
    Trends in ureteral surgery on an academic gynecologic oncology service.
    Gynecol Oncol. 2021 Oct 18. pii: S0090-8258(21)01453.
    PubMed     Abstract available


  273. THOMAIER L, Darst BF, Jewett P, Hoffmann C, et al
    Genetic variants predictive of chemotherapy-induced peripheral neuropathy symptoms in gynecologic cancer survivors.
    Gynecol Oncol. 2021 Oct 18. pii: S0090-8258(21)01450.
    PubMed     Abstract available


  274. LEVINSON K, Beavis AL, Purdy C, Rositch AF, et al
    Corrigendum to "Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis" [Gynecologic Oncology 162 (2021) 532-538].
    Gynecol Oncol. 2021 Oct 12. pii: S0090-8258(21)01386.
    PubMed    


  275. GERNIER F, Gompel A, Rousset-Jablonski C, Kalbacher E, et al
    Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study.
    Gynecol Oncol. 2021 Oct 11. pii: S0090-8258(21)01419.
    PubMed     Abstract available


  276. KONECNY GE, Hendrickson AEW, Davidson TM, Winterhoff BJ, et al
    Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.
    Gynecol Oncol. 2021 Oct 9. pii: S0090-8258(21)01413.
    PubMed     Abstract available


  277. LIU J, Burris H, Wang JS, Barroilhet L, et al
    An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
    Gynecol Oncol. 2021 Oct 6. pii: S0090-8258(21)01403.
    PubMed     Abstract available


  278. EDMONDSON RJ, O'Connell RL, Banerjee S, Mileshkin L, et al
    Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).
    Gynecol Oncol. 2021 Oct 5. pii: S0090-8258(21)01379.
    PubMed     Abstract available


  279. SHAH PD, Wethington SL, Pagan C, Latif N, et al
    Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
    Gynecol Oncol. 2021 Oct 4. pii: S0090-8258(21)01322.
    PubMed     Abstract available


  280. ALHILLI MM, Rybicki L, Carr C, Yao M, et al
    Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma.
    Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01377.
    PubMed     Abstract available


  281. LEE L, Howitt B, Cheng T, King M, et al
    MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma.
    Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01384.
    PubMed     Abstract available


  282. TEWARIE NMSB, van Driel WJ, van Ham M, Wouters MW, et al
    Corrigendum to: Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA) [Gynecologic Oncology Volume 162, Issue 2, August 2021, Pages 331-338].
    Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01392.
    PubMed    


  283. CLAIR KH, Bristow RE
    The urban-rural gap: Disparities in ovarian cancer survival among patients treated in tertiary centers.
    Gynecol Oncol. 2021;163:3-4.
    PubMed    


  284. VAN TRIEST B, Rasing M, van der Velden J, de Hullu J, et al
    Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study.
    Gynecol Oncol. 2021;163:117-124.
    PubMed     Abstract available


    September 2021
  285. SWISHER EM, Kristeleit RS, Oza AM, Tinker AV, et al
    Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01329.
    PubMed     Abstract available


  286. AZZALINI E, Barbazza R, Stanta G, Giorda G, et al
    Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01382.
    PubMed     Abstract available


  287. HOEIJMAKERS YM, Eysbouts YK, Massuger LFAG, Dandis R, et al
    Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01385.
    PubMed     Abstract available


  288. LI JY, Park HS, Huang GS, Young MR, et al
    Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01391.
    PubMed     Abstract available


  289. HA HI, Cho SH, Lim J, Lee YJ, et al
    Incidence and treatment outcomes of ovarian sarcoma compared to epithelial ovarian cancer from the national cancer registry.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01383.
    PubMed     Abstract available


  290. LANDY R, Mathews C, Robertson M, Wiggins CL, et al
    Corrigendum to 'A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States' [Gynecologic Oncology 159 (2020) 344-353].
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01393.
    PubMed    


  291. BRYK S, Katuwal S, Haltia UM, Tapper J, et al
    Parity, menopausal hormone therapy, and risk of ovarian granulosa cell tumor - A population-based case-control study.
    Gynecol Oncol. 2021 Sep 28. pii: S0090-8258(21)01381.
    PubMed     Abstract available


  292. VAN DER PLAS RCJ, Bos AME, Jurgenliemk-Schulz IM, Gerestein CG, et al
    Fertility-sparing surgery and fertility preservation in cervical cancer: The desire for parenthood, reproductive and obstetric outcomes.
    Gynecol Oncol. 2021 Sep 25. pii: S0090-8258(21)01334.
    PubMed     Abstract available


  293. ATASEVEN B, Tripon D, Schwameis R, Harter P, et al
    Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.
    Gynecol Oncol. 2021 Sep 23. pii: S0090-8258(21)01335.
    PubMed     Abstract available


  294. RESHKO LB, Gaskins JT, Rattani A, Farley AA, et al
    Patterns of care and outcomes of radiotherapy or hormone therapy in patients with medically inoperable endometrial adenocarcinoma.
    Gynecol Oncol. 2021 Sep 23. pii: S0090-8258(21)01375.
    PubMed     Abstract available


  295. CONTOS G, Baca Y, Xiu J, Brown J, et al
    Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers.
    Gynecol Oncol. 2021 Sep 22. pii: S0090-8258(21)01380.
    PubMed     Abstract available


  296. JOU J, Charo L, Hom-Tedla M, Coakley K, et al
    Practice patterns and survival in FIGO 2009 stage 3B endometrial cancer.
    Gynecol Oncol. 2021 Sep 21. pii: S0090-8258(21)01374.
    PubMed     Abstract available


  297. LEE SJ, Kim YH, Lee MY, Ko HS, et al
    Ultrasonographic evaluation of ovarian mass for predicting malignancy in pregnant women.
    Gynecol Oncol. 2021 Sep 21. pii: S0090-8258(21)01376.
    PubMed     Abstract available


  298. HUANG T, Townsend MK, Dood RL, Sood AK, et al
    Antihypertensive medication use and ovarian cancer survival.
    Gynecol Oncol. 2021 Sep 20. pii: S0090-8258(21)01378.
    PubMed     Abstract available


  299. WENZEL L, Huang HQ, Cella D, McKinney CO, et al
    Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study.
    Gynecol Oncol. 2021 Sep 18. pii: S0090-8258(21)01326.
    PubMed     Abstract available


  300. COBB LP, Siamakpour-Reihani S, Zhang D, Qin X, et al
    Obesity and altered angiogenic-related gene expression in endometrial cancer.
    Gynecol Oncol. 2021 Sep 15. pii: S0090-8258(21)01308.
    PubMed     Abstract available


  301. POZZAR RA, Hammer MJ, Paul SM, Cooper BA, et al
    Distinct sleep disturbance profiles among patients with gynecologic cancer receiving chemotherapy.
    Gynecol Oncol. 2021 Sep 11. pii: S0090-8258(21)01333.
    PubMed     Abstract available


  302. GAILLARD S, Oaknin A, Ray-Coquard I, Vergote I, et al
    Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
    Gynecol Oncol. 2021 Sep 11. pii: S0090-8258(21)01330.
    PubMed     Abstract available


  303. STRAUBHAR AM, Chi AJ, Zhou QC, Iasonos A, et al
    Pelvic exenteration for recurrent or persistent gynecologic malignancies: Clinical and histopathologic factors predicting recurrence and survival in a modern cohort.
    Gynecol Oncol. 2021 Sep 10. pii: S0090-8258(21)01331.
    PubMed     Abstract available


  304. SOMASEGAR S, Hoppenot C, Kuchta K, Sereika A, et al
    Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers.
    Gynecol Oncol. 2021 Sep 9. pii: S0090-8258(21)01325.
    PubMed     Abstract available


  305. MOSS HA, Chen L, Hershman DL, Davidson B, et al
    Adherence to PARP inhibitor therapy among women with ovarian cancer.
    Gynecol Oncol. 2021 Sep 9. pii: S0090-8258(21)01323.
    PubMed     Abstract available


  306. LUHRS O, Ekdahl L, Geppert B, Lonnerfors C, et al
    Resection of the upper paracervical lymphovascular tissue should be an integral part of a pelvic sentinel lymph node algorithm in early stage cervical cancer.
    Gynecol Oncol. 2021 Sep 8. pii: S0090-8258(21)01328.
    PubMed     Abstract available


  307. WANG Z, Guo E, Yang B, Xiao R, et al
    Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer.
    Gynecol Oncol. 2021 Sep 7. pii: S0090-8258(21)01327.
    PubMed     Abstract available


  308. QIN J, Shahangian S, Saraiya M, Holt H, et al
    Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013-2019.
    Gynecol Oncol. 2021 Sep 7. pii: S0090-8258(21)01321.
    PubMed     Abstract available


  309. WU S, Ding X, Kong Y, Acharya S, et al
    The feature of cervical microbiota associated with the progression of cervical cancer among reproductive females.
    Gynecol Oncol. 2021 Sep 6. pii: S0090-8258(21)01314.
    PubMed     Abstract available


  310. SPONHOLTZ SE, Mogensen O, Hildebrandt MG, Schledermann D, et al
    From FIGO-2009 to FIGO-2018 in women with early-stage cervical cancer; Does the revised staging reflect risk groups?
    Gynecol Oncol. 2021 Sep 6. pii: S0090-8258(21)01324.
    PubMed     Abstract available


  311. WERNER B, Yuwono N, Duggan J, Liu D, et al
    Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer.
    Gynecol Oncol. 2021;162:720-727.
    PubMed     Abstract available


  312. VENKAT P, Salani R
    Changing paradigms in intermediate-risk cervical cancer: Sedlis revisited.
    Gynecol Oncol. 2021;162:527-528.
    PubMed    


  313. CAMPBELL R, King MT, Ross TL, Cohen PA, et al
    Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment.
    Gynecol Oncol. 2021 Sep 1. pii: S0090-8258(21)01320.
    PubMed     Abstract available


  314. AO M, Zheng D, Wang J, Gu X, et al
    Risk factors analysis of persistence, progression and recurrence in vaginal intraepithelial neoplasia.
    Gynecol Oncol. 2021;162:584-589.
    PubMed     Abstract available


  315. GWACHAM NI, McKenzie ND, Fitzgerald ER, Ahmad S, et al
    Neoadjuvant chemotherapy followed by fertility sparing surgery in cervical cancers size 2-4 cm; emerging data and future perspectives.
    Gynecol Oncol. 2021;162:809-815.
    PubMed     Abstract available


    August 2021
  316. FUH KC, Bookman MA, Liu JF, Coleman RL, et al
    Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
    Gynecol Oncol. 2021 Aug 30. pii: S0090-8258(21)01318.
    PubMed     Abstract available


  317. ACKROYD SA, Shih YT, Kim B, Lee NK, et al
    A look at the gynecologic oncologist workforce - Are we meeting patient demand?
    Gynecol Oncol. 2021 Aug 26. pii: S0090-8258(21)01311.
    PubMed     Abstract available


  318. STEENBEEK MP, van Bommel MHD, Harmsen MG, Hoogerbrugge N, et al
    Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy.
    Gynecol Oncol. 2021 Aug 26. pii: S0090-8258(21)01317.
    PubMed     Abstract available


  319. EBINA Y, Yamagami W, Kobayashi Y, Tabata T, et al
    Clinicopathological characteristics and prognostic factors of ovarian granulosa cell tumors: A JSGO-JSOG joint study.
    Gynecol Oncol. 2021 Aug 25. pii: S0090-8258(21)01310.
    PubMed     Abstract available


  320. MATZ M, Weir HK, Alkhalawi E, Coleman MP, et al
    Disparities in cervical cancer survival in the United States by race and stage at diagnosis: An analysis of 138,883 women diagnosed between 2001 and 2014 (CONCORD-3).
    Gynecol Oncol. 2021 Aug 25. pii: S0090-8258(21)01312.
    PubMed     Abstract available


  321. POZZAR RA, Xiong N, Hong F, Wright AA, et al
    Perceived patient-centered communication, quality of life, and symptom burden in individuals with ovarian cancer.
    Gynecol Oncol. 2021 Aug 25. pii: S0090-8258(21)00652.
    PubMed     Abstract available


  322. TAMURA R, Yoshihara K, Matsuo K, Yachida N, et al
    Proposing a molecular classification associated with hypercoagulation in ovarian clear cell carcinoma.
    Gynecol Oncol. 2021 Aug 24. pii: S0090-8258(21)01307.
    PubMed     Abstract available


  323. SOMASEGAR S, Weiss AS, Norquist BM, Khasnavis N, et al
    Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.
    Gynecol Oncol. 2021 Aug 24. pii: S0090-8258(21)01315.
    PubMed     Abstract available


  324. TYMON-ROSARIO J, Bonazzoli E, Bellone S, Manzano A, et al
    DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
    Gynecol Oncol. 2021 Aug 24. pii: S0090-8258(21)01313.
    PubMed     Abstract available


  325. O'MALLEY DM, Oaknin A, Monk BJ, Selle F, et al
    Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
    Gynecol Oncol. 2021 Aug 24. pii: S0090-8258(21)01316.
    PubMed     Abstract available


  326. D'AMORA P, Silva IDCG, Tewari KS, Bristow RE, et al
    Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis.
    Gynecol Oncol. 2021 Aug 23. pii: S0090-8258(21)00646.
    PubMed     Abstract available


  327. MANNING-GEIST BL, Gatius S, Liu Y, Gil M, et al
    Diagnosis and management of an endometrial cancer patient with Cowden syndrome.
    Gynecol Oncol. 2021 Aug 23. pii: S0090-8258(21)01292.
    PubMed     Abstract available


  328. D'ALESSANDRIS N, Travaglino A, Santoro A, Arciuolo D, et al
    TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
    Gynecol Oncol. 2021 Aug 23. pii: S0090-8258(21)01309.
    PubMed     Abstract available


  329. COWAN M, Swetzig WM, Adorno-Cruz V, Pineda MJ, et al
    Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.
    Gynecol Oncol. 2021 Aug 18. pii: S0090-8258(21)00650.
    PubMed     Abstract available


  330. BANERJEE SN, Tang M, O'Connell RL, Sjoquist K, et al
    A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.
    Gynecol Oncol. 2021 Aug 16. pii: S0090-8258(21)00586.
    PubMed     Abstract available


  331. HUEPENBECKER SP, Iniesta MD, Zorrilla-Vaca A, Ramirez PT, et al
    Incidence of acute kidney injury after open gynecologic surgery in an enhanced recovery after surgery pathway.
    Gynecol Oncol. 2021 Aug 13. pii: S0090-8258(21)00651.
    PubMed     Abstract available


  332. LUTGENDORF SK, Ramirez E, Schrepf A, Valentine MC, et al
    Rural residence is related to shorter survival in epithelial ovarian cancer patients.
    Gynecol Oncol. 2021 Aug 13. pii: S0090-8258(21)00601.
    PubMed     Abstract available


  333. PARK M, Lim J, Lee JA, Park HJ, et al
    Incidence and outcomes of malignant ovarian germ cell tumors in Korea, 1999-2017.
    Gynecol Oncol. 2021 Aug 12. pii: S0090-8258(21)00645.
    PubMed     Abstract available


  334. WU Y, Huang J, Ivan C, Sun Y, et al
    MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer.
    Gynecol Oncol. 2021 Aug 11. pii: S0090-8258(21)00648.
    PubMed     Abstract available


  335. WETHINGTON SL, Wahner-Hendrickson AE, Swisher EM, Kaufmann SH, et al
    PARP inhibitor maintenance for primary ovarian cancer - A missed opportunity for precision medicine.
    Gynecol Oncol. 2021 Aug 11. pii: S0090-8258(21)00647.
    PubMed    


  336. AREND RC, Goel N, Roane BM, Foxall ME, et al
    Systematic Next Generation Sequencing is feasible in clinical practice and identifies opportunities for targeted therapy in women with uterine cancer: Results from a prospective cohort study.
    Gynecol Oncol. 2021 Aug 6. pii: S0090-8258(21)00579.
    PubMed     Abstract available


  337. TYMON-ROSARIO J, Siegel ER, Bellone S, Harold J, et al
    Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu.
    Gynecol Oncol. 2021 Aug 6. pii: S0090-8258(21)00599.
    PubMed     Abstract available


  338. WENTZENSEN N, O'Brien KM
    Talc, body powder, and ovarian cancer: A summary of the epidemiologic evidence.
    Gynecol Oncol. 2021 Aug 5. pii: S0090-8258(21)00598.
    PubMed     Abstract available


  339. COLOMBO N, Moore K, Scambia G, Oaknin A, et al
    Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.
    Gynecol Oncol. 2021 Aug 2. pii: S0090-8258(21)00578.
    PubMed     Abstract available


  340. GREEN AK, Makker V
    Novel therapy in endometrial cancer: How much will we pay?
    Gynecol Oncol. 2021;162:243-244.
    PubMed    


  341. SALANI R, Liu JF
    The American Society of Clinical Oncology 2021 annual (virtual) meeting: A review and summary of selected abstracts.
    Gynecol Oncol. 2021;162:245-248.
    PubMed    


  342. GROENEWEG JW, Roze JF, Peters EDJ, Sereno F, et al
    FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring.
    Gynecol Oncol. 2021;162:413-420.
    PubMed     Abstract available


  343. KELTTO N, Leivonen A, Pankakoski M, Sarkeala T, et al
    Cervical testing beyond the screening target age - A register-based cohort study from Finland.
    Gynecol Oncol. 2021;162:315-321.
    PubMed     Abstract available


    July 2021
  344. BANTIE L, Tadesse S, Likisa J, Yu M, et al
    Erratum to "A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer" [Gynecologic Oncology 159 (2020) 827-838].
    Gynecol Oncol. 2021 Jul 30. pii: S0090-8258(21)00580.
    PubMed    


  345. HRUDA M, Robova H, Rob L, Halaska MJ, et al
    Twenty years of experience with less radical fertility-sparing surgery in early-stage cervical cancer: Oncological outcomes.
    Gynecol Oncol. 2021 Jul 27. pii: S0090-8258(21)00593.
    PubMed     Abstract available


  346. VILLANUEVA C, Chang J, Ziogas A, Bristow RE, et al
    Ambient air pollution and ovarian cancer survival in California.
    Gynecol Oncol. 2021 Jul 27. pii: S0090-8258(21)00602.
    PubMed     Abstract available


  347. NANEZ A, Stram DA, Garcia C, Powell CB, et al
    Ovarian cancer surveillance in the clinical follow up of women with known BRCA1 or BRCA2 pathogenic variants in a large health care system.
    Gynecol Oncol. 2021 Jul 27. pii: S0090-8258(21)00600.
    PubMed     Abstract available


  348. PARK AB, Darcy KM, Tian C, Casablanca Y, et al
    Racial disparities in survival among women with endometrial cancer in an equal access system.
    Gynecol Oncol. 2021 Jul 26. pii: S0090-8258(21)00584.
    PubMed     Abstract available


  349. LAZURKO C, Clark M, Pulman K, Lennox G, et al
    Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review.
    Gynecol Oncol. 2021 Jul 26. pii: S0090-8258(21)00589.
    PubMed     Abstract available


  350. MARCHETTI C, Rosati A, De Felice F, Boccia SM, et al
    Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis.
    Gynecol Oncol. 2021 Jul 23. pii: S0090-8258(21)00587.
    PubMed     Abstract available


  351. HICKEY M, Moss KM, Krejany EO, Wrede CD, et al
    What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12months after premenopausal risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2021 Jul 23. pii: S0090-8258(21)00591.
    PubMed     Abstract available


  352. BASARAN D, Boerner T, Suhner J, Sassine D, et al
    Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy.
    Gynecol Oncol. 2021 Jul 23. pii: S0090-8258(21)00592.
    PubMed     Abstract available


  353. TIWARI R, Narayanan GS, Reddy VP, Vishwanathan B, et al
    Impact of nodal boost irradiation and MR-based brachytherapy on oncologic outcomes in node-positive cervical cancer.
    Gynecol Oncol. 2021 Jul 22. pii: S0090-8258(21)00585.
    PubMed     Abstract available


  354. EOH KJ, Park EY, Chang YJ, Ha HI, et al
    The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Jul 22. pii: S0090-8258(21)00590.
    PubMed     Abstract available


  355. MOSS HA, Perhanidis JA, Havrilesky LJ, Secord AA, et al
    Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2021 Jul 20. pii: S0090-8258(21)00588.
    PubMed     Abstract available


  356. CIBULA D, Rob L, Mallmann P, Knapp P, et al
    Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
    Gynecol Oncol. 2021 Jul 19. pii: S0090-8258(21)00533.
    PubMed     Abstract available


  357. AVIKI EM, Schleicher SM, Boyd L, Liang M, et al
    The oncology care model and the future of alternative payment models: A gynecologic oncology perspective.
    Gynecol Oncol. 2021 Jul 19. pii: S0090-8258(21)00576.
    PubMed    


  358. DE NONNEVILLE A, Zemmour C, Frank S, Joly F, et al
    Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.
    Gynecol Oncol. 2021 Jul 19. pii: S0090-8258(21)00581.
    PubMed     Abstract available


  359. MURAKAMI N, Ando K, Murata M, Murata K, et al
    Why not de-intensification for uterine cervical cancer?
    Gynecol Oncol. 2021 Jul 19. pii: S0090-8258(21)00583.
    PubMed     Abstract available


  360. ZENG H, Chen L, Zhang M, Luo Y, et al
    Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer.
    Gynecol Oncol. 2021 Jul 15. pii: S0090-8258(21)00577.
    PubMed     Abstract available


  361. RASMUSSEN M, Lim K, Rambech E, Andersen MH, et al
    Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
    Gynecol Oncol. 2021 Jul 15. pii: S0090-8258(21)00531.
    PubMed     Abstract available


  362. GHONIEM K, Larish AM, Dinoi G, Zhou XC, et al
    Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An international multi-institutional study.
    Gynecol Oncol. 2021 Jul 14. pii: S0090-8258(21)00526.
    PubMed     Abstract available


  363. ZONG L, Sun Z, Mo S, Lu Z, et al
    PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer.
    Gynecol Oncol. 2021 Jul 13. pii: S0090-8258(21)00539.
    PubMed     Abstract available


  364. KURODA Y, Chiyoda T, Kawaida M, Nakamura K, et al
    ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.
    Gynecol Oncol. 2021 Jul 13. pii: S0090-8258(21)00536.
    PubMed     Abstract available


  365. BACKES FJ, Wei L, Chen M, Hill K, et al
    Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
    Gynecol Oncol. 2021 Jul 13. pii: S0090-8258(21)00528.
    PubMed     Abstract available


  366. TRAVAGLINO A, Raffone A, Santoro A, Raimondo D, et al
    Clear cell endometrial carcinomas with mismatch repair deficiency have a favorable prognosis: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00537.
    PubMed     Abstract available


  367. HERMENS M, van Altena AM, Bulten J, van Vliet HAAM, et al
    Increased incidence of ovarian cancer in both endometriosis and adenomyosis.
    Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00535.
    PubMed     Abstract available


  368. POLI JG, Paiva G, Freitas F, Mora P, et al
    Folinic acid rescue during methotrexate treatment for low-risk gestational trophoblastic neoplasia - How much is just right?
    Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00551.
    PubMed     Abstract available


  369. HUFFMAN DL, Jayakrishnan TT, Shankar K, Peterson CE, et al
    Disparities in ovarian cancer treatment and overall survival according to race: An update.
    Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00541.
    PubMed     Abstract available


  370. KIM SR, Malcolmson J, Li X, Bernardini MQ, et al
    The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2021 Jul 10. pii: S0090-8258(21)00540.
    PubMed     Abstract available


  371. VAN DER PLOEG P, Uittenboogaard A, Thijs AMJ, Westgeest HM, et al
    The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2021 Jul 10. pii: S0090-8258(21)00538.
    PubMed     Abstract available


  372. HAESEN J, Salihi R, Van Gorp T, Van Nieuwenhuysen E, et al
    Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria.
    Gynecol Oncol. 2021 Jul 9. pii: S0090-8258(21)00522.
    PubMed     Abstract available


  373. VICTOOR J, Borght SV, Spans L, Lehnert S, et al
    Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study.
    Gynecol Oncol. 2021 Jul 9. pii: S0090-8258(21)00527.
    PubMed     Abstract available


  374. CUZICK J, Du R, Adcock R, Kinney W, et al
    Uptake of co-testing with HPV and cytology for cervical screening: A population-based evaluation in the United States.
    Gynecol Oncol. 2021 Jul 9. pii: S0090-8258(21)00525.
    PubMed     Abstract available


  375. SULLIVAN MW, Philp L, Kanbergs AN, Safdar N, et al
    Lymph node assessment at the time of hysterectomy has limited clinical utility for patients with pre-cancerous endometrial lesions.
    Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00534.
    PubMed     Abstract available


  376. GRUNER M, Chambers LM, Yao M, Chichura A, et al
    Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer.
    Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00530.
    PubMed     Abstract available


  377. GADDUCCI A, Multinu F, Cosio S, Carinelli S, et al
    Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
    Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00529.
    PubMed     Abstract available


  378. KRASNER CN, Campos SM, Young CL, Chadda KR, et al
    Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
    Gynecol Oncol. 2021 Jul 6. pii: S0090-8258(21)00532.
    PubMed     Abstract available


  379. HILLMAN RT, Lin DI, Lawson B, Gershenson DM, et al
    Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors.
    Gynecol Oncol. 2021 Jul 5. pii: S0090-8258(21)00518.
    PubMed     Abstract available


  380. STRAUBHAR AM, Dalton L, Rolston A, McCool K, et al
    Optimization of postoperative opioid prescriptions in gynecologic oncology: Striking a balance between opioid reduction and pain control.
    Gynecol Oncol. 2021 Jul 2. pii: S0090-8258(21)00519.
    PubMed     Abstract available


  381. SPONHOLTZ SE, Mogensen O, Hildebrandt MG, Schledermann D, et al
    Sentinel lymph node mapping in early-stage cervical cancer - A national prospective multicenter study (SENTIREC trial).
    Gynecol Oncol. 2021 Jul 2. pii: S0090-8258(21)00512.
    PubMed     Abstract available


  382. SALVADO A, Miralpeix E, Sole-Sedeno JM, Kanjou N, et al
    Predictor factors for conservative management of cervical intraepithelial neoplasia grade 2: Cytology and HPV genotyping.
    Gynecol Oncol. 2021 Jul 2. pii: S0090-8258(21)00515.
    PubMed     Abstract available


    June 2021
  383. LEVINSON K, Beavis AL, Purdy C, Rositch AF, et al
    Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis.
    Gynecol Oncol. 2021 Jun 30. pii: S0090-8258(21)00511.
    PubMed     Abstract available


  384. BENOIT L DR, Zerbib J Dr, Koual M Dr, Nguyen-Xuan HT Dr, et al
    What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery?
    Gynecol Oncol. 2021 Jun 30. pii: S0090-8258(21)00521.
    PubMed     Abstract available


  385. CHATZISTAMATIOU K, Tsertanidou A, Moysiadis T, Mouchtaropoulou E, et al
    Comparison of different strategies for the triage to colposcopy of women tested high-risk HPV positive on self-collected cervicovaginal samples.
    Gynecol Oncol. 2021 Jun 28. pii: S0090-8258(21)00516.
    PubMed     Abstract available


  386. FEIGENBERG T, Cormier B, Gotlieb WH, Jegatheeswaran K, et al
    Factors associated with an increased risk of recurrence in patients diagnosed with high-grade endometrial cancer undergoing minimally invasive surgery: A study of the society of gynecologic oncology (GOC) community of practice (CoP).
    Gynecol Oncol. 2021 Jun 25. pii: S0090-8258(21)00493.
    PubMed     Abstract available


  387. JIA N, Che X, Jiang Y, Zhu M, et al
    Synergistic effects of a combined treatment of PI3K/mTOR dual inhibitor LY3023414 and carboplatin on human endometrial carcinoma.
    Gynecol Oncol. 2021 Jun 25. pii: S0090-8258(21)00495.
    PubMed     Abstract available


  388. SAFRA T, Waissengrin B, Gerber D, Bernstein-Molho R, et al
    Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.
    Gynecol Oncol. 2021 Jun 22. pii: S0090-8258(21)00489.
    PubMed     Abstract available


  389. VAN KEER S, Peeters E, Vanden Broeck D, De Sutter P, et al
    Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol.
    Gynecol Oncol. 2021 Jun 22. pii: S0090-8258(21)00490.
    PubMed     Abstract available


  390. GRAY HJ, Secord AA
    Society of Gynecologic Oncology (SGO) 2021 meeting report: Scaling new heights with innovative cancer care.
    Gynecol Oncol. 2021 Jun 21. pii: S0090-8258(21)00332.
    PubMed    


  391. WRIGHT JD, Huang Y, Melamed A, Albright BB, et al
    Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer.
    Gynecol Oncol. 2021 Jun 19. pii: S0090-8258(21)00496.
    PubMed     Abstract available


  392. BARRINGTON DA, Haight PJ, Calhoun C, Tubbs C, et al
    Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2021 Jun 17. pii: S0090-8258(21)00494.
    PubMed     Abstract available


  393. ZHANG G, Zhang Y, He F, Wu H, et al
    Preoperative controlling nutritional status (CONUT) score is a prognostic factor for early-stage cervical cancer patients with high-risk factors.
    Gynecol Oncol. 2021 Jun 17. pii: S0090-8258(21)00492.
    PubMed     Abstract available


  394. WAGAR MK, Sobecki JN, Chandereng T, Hartenbach EM, et al
    Postoperative venous thromboembolism in gynecologic oncology patients undergoing minimally invasive surgery: Does modality matter?
    Gynecol Oncol. 2021 Jun 17. pii: S0090-8258(21)00491.
    PubMed     Abstract available


  395. BALDEWPERSAD TEWARIE NMS, van Driel WJ, van Ham M, Wouters MW, et al
    Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA).
    Gynecol Oncol. 2021 Jun 16. pii: S0090-8258(21)00436.
    PubMed     Abstract available


  396. JIANG C, Li Z
    Performance validation of the Mayo triage algorithm applied to individualize surgical management of advanced epithelial ovarian cancer.
    Gynecol Oncol. 2021 Jun 16. pii: S0090-8258(21)00483.
    PubMed     Abstract available


  397. YUAN R, Zhang C, Li Q, Ji M, et al
    The impact of marital status on stage at diagnosis and survival of female patients with breast and gynecologic cancers: A meta-analysis.
    Gynecol Oncol. 2021 Jun 14. pii: S0090-8258(21)00488.
    PubMed     Abstract available


  398. ZAMORANO AS, Wilson EM, Liu J, Leon A, et al
    Text-message-based behavioral weight loss for endometrial cancer survivors with obesity: A randomized controlled trial.
    Gynecol Oncol. 2021 Jun 14. pii: S0090-8258(21)00487.
    PubMed     Abstract available


  399. IMBODEN S, Nastic D, Ghaderi M, Rydberg F, et al
    Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.
    Gynecol Oncol. 2021 Jun 11. pii: S0090-8258(21)00432.
    PubMed     Abstract available


  400. BENITO V, Lubrano A, Perez-Regadera JF, Torne A, et al
    Postreatment squamous cell carcinoma antigen as a survival prognostic factor in patients with locally advanced cervical cancer. A Spanish multicenter study. The SEGO Spain-GOG group.
    Gynecol Oncol. 2021 Jun 9. pii: S0090-8258(21)00485.
    PubMed     Abstract available


  401. FAN Y, Zhang YF, Wang MY, Mu Y, et al
    Influence of lymph node involvement or lymphadenectomy on prognosis of patients with borderline ovarian tumors: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Jun 9. pii: S0090-8258(21)00439.
    PubMed     Abstract available


  402. MATANES E, Eisenberg N, Lau S, Salvador S, et al
    Absence of prognostic value of lymphovascular space invasion in patients with endometrial cancer and negative sentinel lymph nodes.
    Gynecol Oncol. 2021 Jun 9. pii: S0090-8258(21)00446.
    PubMed     Abstract available


  403. RONSINI C, Anchora LP, Restaino S, Fedele C, et al
    The role of semiquantitative evaluation of lympho-vascular space invasion in early stage cervical cancer patients.
    Gynecol Oncol. 2021 Jun 9. pii: S0090-8258(21)00482.
    PubMed     Abstract available


  404. HICKEY M, Moss KM, Krejany EO, Wrede CD, et al
    What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12months after premenopausal risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2021 Jun 8. pii: S0090-8258(21)00442.
    PubMed     Abstract available


  405. VAN DER ZANDEN V, van Soolingen NJ, Viddeleer AR, Trum JW, et al
    Low preoperative skeletal muscle density is predictive for negative postoperative outcomes in older women with ovarian cancer.
    Gynecol Oncol. 2021 Jun 7. pii: S0090-8258(21)00445.
    PubMed     Abstract available


  406. AGHAJANIAN C, Bookman MA, Fleming GF, Swisher EM, et al
    Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
    Gynecol Oncol. 2021 Jun 7. pii: S0090-8258(21)00437.
    PubMed     Abstract available


  407. ACKROYD SA, Huang ES, Kurnit KC, Lee NK, et al
    Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.
    Gynecol Oncol. 2021 Jun 5. pii: S0090-8258(21)00444.
    PubMed     Abstract available


  408. DOSSUS L, Kouloura E, Biessy C, Viallon V, et al
    Prospective analysis of circulating metabolites and endometrial cancer risk.
    Gynecol Oncol. 2021 Jun 5. pii: S0090-8258(21)00447.
    PubMed     Abstract available


  409. JOU J, Brodsky A, Charo L, Binder P, et al
    Trends and geographic variation in women's representation as principal investigators (PI) in phase 3 gynecologic oncology clinical trials.
    Gynecol Oncol. 2021 Jun 4. pii: S0090-8258(21)00443.
    PubMed     Abstract available


  410. CASPER AC, Parsons MW, Chipman J, Burt LM Jr, et al
    Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00440.
    PubMed     Abstract available


  411. LI S, Bercow AS, Falzone M, Kalyanaraman R, et al
    Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00438.
    PubMed     Abstract available


  412. HANLEY GE, Kaur P, Berchuck A, Chase A, et al
    Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00427.
    PubMed     Abstract available


  413. MILLS JM, Morgan JR, Dhaliwal A, Perkins RB, et al
    Eligibility for cervical cancer screening exit: Comparison of a national and safety net cohort.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00441.
    PubMed     Abstract available


  414. ALVAREZ SECORD A, O'Malley DM, Sood AK, Westin SN, et al
    Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
    Gynecol Oncol. 2021 Jun 2. pii: S0090-8258(21)00424.
    PubMed     Abstract available


  415. MOUKARZEL LA, Braxton KF, Zhou QC, Pedra Nobre S, et al
    Non-exenterative surgical management of recurrent endometrial carcinoma.
    Gynecol Oncol. 2021 Jun 2. pii: S0090-8258(21)00426.
    PubMed     Abstract available


  416. RAFFONE A, Travaglino A, Raimondo D, Neola D, et al
    Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma.
    Gynecol Oncol. 2021 Jun 1. pii: S0090-8258(21)00435.
    PubMed     Abstract available


  417. SUE-A-QUAN R, Patel PG, Shakfa N, Nyi MN, et al
    Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary.
    Gynecol Oncol. 2021 Jun 1. pii: S0090-8258(21)00406.
    PubMed     Abstract available


  418. SHARMA A, Singh M, Chauhan R, Malik PS, et al
    Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
    Gynecol Oncol. 2021 Jun 1. pii: S0090-8258(21)00431.
    PubMed     Abstract available


  419. PEI X, Xiang L, Chen W, Jiang W, et al
    The next generation sequencing of cancer-related genes in small cell neuroendocrine carcinoma of the cervix.
    Gynecol Oncol. 2021;161:779-786.
    PubMed     Abstract available


  420. CHIAPPA V, Interlenghi M, Salvatore C, Bertolina F, et al
    Using rADioMIcs and machine learning with ultrasonography for the differential diagnosis of myometRiAL tumors (the ADMIRAL pilot study). Radiomics and differential diagnosis of myometrial tumors.
    Gynecol Oncol. 2021;161:838-844.
    PubMed     Abstract available


  421. SEZEN D, Patel RR, Tang C, Onstad M, et al
    Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma.
    Gynecol Oncol. 2021;161:645-652.
    PubMed     Abstract available


  422. ZACH D, Avall-Lundqvist E, Falconer H, Hellman K, et al
    Patterns of recurrence and survival in vulvar cancer: A nationwide population-based study.
    Gynecol Oncol. 2021;161:748-754.
    PubMed     Abstract available


    May 2021
  423. SERT BM, Kristensen GB, Kleppe A, Dorum A, et al
    Long-term oncological outcomes and recurrence patterns in early-stage cervical cancer treated with minimally invasive versus abdominal radical hysterectomy: The Norwegian Radium Hospital experience.
    Gynecol Oncol. 2021 May 31. pii: S0090-8258(21)00434.
    PubMed     Abstract available


  424. CHAMBERS LM, Chalif J, Yao M, Chichura A, et al
    Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Gynecol Oncol. 2021 May 31. pii: S0090-8258(21)00409.
    PubMed     Abstract available


  425. BRODEUR MN, Dejean R, Beauchemin MC, Samouelian V, et al
    Oncologic outcomes in the era of modern radiation therapy using FIGO 2018 staging system for cervical cancer.
    Gynecol Oncol. 2021 May 28. pii: S0090-8258(21)00429.
    PubMed     Abstract available


  426. SONG F, Belinson JL, Yan P, Huang X, et al
    Evaluation of p16(INK4a) immunocytology and human papillomavirus (HPV) genotyping triage after primary HPV cervical cancer screening on self-samples in China.
    Gynecol Oncol. 2021 May 28. pii: S0090-8258(21)00410.
    PubMed     Abstract available


  427. FRANGOU E, Bertelli G, Love S, Mackean MJ, et al
    OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer.
    Gynecol Oncol. 2021 May 28. pii: S0090-8258(21)00430.
    PubMed     Abstract available


  428. HAVRILESKY LJ, Scott AL, Davidson BA, Secord AA, et al
    The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.
    Gynecol Oncol. 2021 May 27. pii: S0090-8258(21)00428.
    PubMed     Abstract available


  429. DE JONG JM, Hoogendam JP, Braat AJAT, Zweemer RP, et al
    The feasibility of folate receptor alpha- and HER2-targeted intraoperative fluorescence-guided cytoreductive surgery in women with epithelial ovarian cancer: A systematic review.
    Gynecol Oncol. 2021 May 27. pii: S0090-8258(21)00423.
    PubMed     Abstract available


  430. JANDA M, Robledo KP, Gebski V, Armes JE, et al
    Corrigendum to "Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial" [Gynecologic Oncology 161 (2021) 143-151].
    Gynecol Oncol. 2021 May 27. pii: S0090-8258(21)00422.
    PubMed    


  431. MANNING-GEIST BL, Chi DS, Long Roche K, Zivanovic O, et al
    Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
    Gynecol Oncol. 2021 May 25. pii: S0090-8258(21)00421.
    PubMed     Abstract available


  432. TOBONI MD, Crane EK, Brown J, Shushkevich A, et al
    State of the science: Uterine carcinosarcomas: From pathology to practice.
    Gynecol Oncol. 2021 May 21. pii: S0090-8258(21)00362.
    PubMed     Abstract available


  433. LIN J, Sharaf RN, Saganty R, Ahsan D, et al
    Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis.
    Gynecol Oncol. 2021 May 19. pii: S0090-8258(21)00407.
    PubMed     Abstract available


  434. WINER I, Kim C, Gehrig P
    Neuroendocrine tumors of the gynecologic tract update.
    Gynecol Oncol. 2021 May 19. pii: S0090-8258(21)00359.
    PubMed    


  435. HEMMINGSEN CH, Kjaer SK, Bennetsen AKK, Dehlendorff C, et al
    The association of reproductive factors with risk of non-epithelial ovarian cancer and comparison with serous ovarian cancer.
    Gynecol Oncol. 2021 May 17. pii: S0090-8258(21)00404.
    PubMed     Abstract available


  436. ISHIKAWA M, Shibata T, Iwata T, Nishio S, et al
    A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Prim
    Gynecol Oncol. 2021 May 17. pii: S0090-8258(21)00403.
    PubMed     Abstract available


  437. KIM SI, Yoon S, Kim TM, Cho JY, et al
    Prognostic implications of body composition change during primary treatment in patients with ovarian cancer: A retrospective study using an artificial intelligence-based volumetric technique.
    Gynecol Oncol. 2021 May 13. pii: S0090-8258(21)00363.
    PubMed     Abstract available


  438. TRAN DT, Vo VK, Le MT, Chuang L, et al
    Copenhagen Index versus ROMA in preoperative ovarian malignancy risk stratification: Result from the first Vietnamese prospective cohort study.
    Gynecol Oncol. 2021 May 13. pii: S0090-8258(21)00360.
    PubMed     Abstract available


  439. MATSUO K, Mandelbaum RS, Klar M, Ciesielski KM, et al
    Decreasing utilization of minimally invasive hysterectomy for cervical cancer in the United States.
    Gynecol Oncol. 2021 May 12. pii: S0090-8258(21)00364.
    PubMed     Abstract available


  440. CABRERA S, Barahona-Orpinell M, Almansa-Gonzalez C, Padilla-Iserte P, et al
    Combined use of ICG and technetium does not improve sentinel lymph node detection in endometrial cancer: Results of the COMBITEC study.
    Gynecol Oncol. 2021 May 12. pii: S0090-8258(21)00361.
    PubMed     Abstract available


  441. ZAMMARRELLI WA 3RD, Afonso AM, Broach V, Sonoda Y, et al
    Sentinel lymph node biopsy in patients with endometrial cancer and an indocyanine green or iodinated contrast reaction - A proposed management algorithm.
    Gynecol Oncol. 2021 May 12. pii: S0090-8258(21)00405.
    PubMed     Abstract available


  442. MCALARNEN LA, Tsaih SW, Aliani R, Simske NM, et al
    Virtual visits among gynecologic oncology patients during the COVID-19 pandemic are accessible across the social vulnerability spectrum.
    Gynecol Oncol. 2021 May 11. pii: S0090-8258(21)00357.
    PubMed     Abstract available


  443. GONZALEZ R, Kurtovic K, Habib AS, Ryan ES, et al
    A quality improvement initiative to reduce venous thromboembolism on a gynecologic oncology service.
    Gynecol Oncol. 2021 May 11. pii: S0090-8258(21)00355.
    PubMed     Abstract available


  444. FUCINARI J, Elshaikh MA, Ruterbusch JJ, Khalil R, et al
    The impact of race, comorbid conditions and obesity on survival endpoints in women with high grade endometrial carcinoma.
    Gynecol Oncol. 2021 May 10. pii: S0090-8258(21)00356.
    PubMed     Abstract available


  445. HICKEY M, Moss KM, Mishra GD, Krejany EO, et al
    What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    Gynecol Oncol. 2021 May 7. pii: S0090-8258(21)00358.
    PubMed     Abstract available


  446. JEONG SY, Cho YJ, Ryu JY, Choi JJ, et al
    Establishment and preclinical application of a patient-derived xenograft model for uterine cancer.
    Gynecol Oncol. 2021 May 7. pii: S0090-8258(21)00348.
    PubMed     Abstract available


  447. CAO L, Wei M, Liu Y, Fu J, et al
    Validation of American College of Radiology Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US): Analysis on 1054 adnexal masses.
    Gynecol Oncol. 2021 May 6. pii: S0090-8258(21)00351.
    PubMed     Abstract available


  448. CHAM S, Huang Y, Melamed A, Worley MJ Jr, et al
    Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival.
    Gynecol Oncol. 2021 May 5. pii: S0090-8258(21)00352.
    PubMed     Abstract available


  449. BAGARIA M, Wentzensen N, Clarke M, Hopkins MR, et al
    Quantifying procedural pain associated with office gynecologic tract sampling methods.
    Gynecol Oncol. 2021 May 3. pii: S0090-8258(21)00353.
    PubMed     Abstract available


  450. GAMBLE CR, Huang Y, Wright JD, Hou JY, et al
    Precision medicine testing in ovarian cancer: The growing inequity between patients with commercial vs medicaid insurance.
    Gynecol Oncol. 2021 May 3. pii: S0090-8258(21)00345.
    PubMed     Abstract available


  451. HOW JA, Patel S, Fellman B, Lu KH, et al
    Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer.
    Gynecol Oncol. 2021 May 3. pii: S0090-8258(21)00354.
    PubMed     Abstract available


  452. SIMS TT, Boruta DM
    Sentinel lymph node isolated tumor cells in early staged endometrioid endometrial cancer: Utility or futility?
    Gynecol Oncol. 2021;161:331-332.
    PubMed    


  453. AIOB A, Naskovica K, Sharon A, Bornstein J, et al
    A possible association between hydatidiform mole and the COVID-19 pandemic: A retrospective cohort study.
    Gynecol Oncol. 2021;161:454-457.
    PubMed     Abstract available


  454. PRIESKE K, Woelber L, Muallem MZ, Eulenburg C, et al
    Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study.
    Gynecol Oncol. 2021;161:442-448.
    PubMed     Abstract available


  455. BOHLIN KS, Bruno AK, von Knorring C, Rahm C, et al
    Accuracy of computerized tomography in the preoperative evaluation of metastases in primary vulvar cancer - A population-based study.
    Gynecol Oncol. 2021;161:449-453.
    PubMed     Abstract available


  456. KOUAL M, Benoit L, Nguyen-Xuan HT, Bentivegna E, et al
    Diagnostic value of indocyanine green fluorescence guided sentinel lymph node biopsy in vulvar cancer: A systematic review.
    Gynecol Oncol. 2021;161:436-441.
    PubMed     Abstract available


  457. GILLEN J, Miller A, Bell-McGuinn KM, Schilder RJ, et al
    Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
    Gynecol Oncol. 2021;161:512-515.
    PubMed     Abstract available


    April 2021
  458. SUN Z, Wang S, Yang R, Li X, et al
    Gestational diabetes mellitus and risks of gynecologic cancers: Results from a nationwide Swedish twin study.
    Gynecol Oncol. 2021 Apr 29. pii: S0090-8258(21)00266.
    PubMed     Abstract available


  459. BOGANI G, Ray-Coquard I, Concin N, Ngoi NYL, et al
    Uterine serous carcinoma.
    Gynecol Oncol. 2021 Apr 29. pii: S0090-8258(21)00349.
    PubMed     Abstract available


  460. PIEDIMONTE S, Li S, Laframboise S, Ferguson SE, et al
    Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center.
    Gynecol Oncol. 2021 Apr 28. pii: S0090-8258(21)00350.
    PubMed     Abstract available


  461. MULLINS MA, Ruterbusch JJ, Clarke P, Uppal S, et al
    Continuity of care and receipt of aggressive end of life care among women dying of ovarian cancer.
    Gynecol Oncol. 2021 Apr 27. pii: S0090-8258(21)00344.
    PubMed     Abstract available


  462. DILLEY S, Huh W, Blechter B, Rositch AF, et al
    It's time to re-evaluate cervical Cancer screening after age 65.
    Gynecol Oncol. 2021 Apr 26. pii: S0090-8258(21)00347.
    PubMed     Abstract available


  463. MARAMAI M, Achilarre MT, Aloisi A, Betella I, et al
    Cervical re-injection of indocyanine green to improve sentinel lymph node detection in endometrial cancer.
    Gynecol Oncol. 2021 Apr 24. pii: S0090-8258(21)00346.
    PubMed     Abstract available


  464. KASUGA Y, Ikenoue S, Tanaka M, Ochiai D, et al
    Management of pregnancy after radical trachelectomy.
    Gynecol Oncol. 2021 Apr 23. pii: S0090-8258(21)00343.
    PubMed     Abstract available


  465. GIANNONE G, Scotto G, Katsaros D, De Giorgi U, et al
    Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature.
    Gynecol Oncol. 2021 Apr 22. pii: S0090-8258(21)00328.
    PubMed     Abstract available


  466. RUBINSTEIN MM, Dickinson S, Narayan P, Zhou Q, et al
    Bevacizumab in advanced endometrial cancer.
    Gynecol Oncol. 2021 Apr 21. pii: S0090-8258(21)00326.
    PubMed     Abstract available


  467. LUCCHINI SM, Esteban A, Nigra MA, Palacios AT, et al
    Updates on conservative management of endometrial cancer in patients younger than 45 years.
    Gynecol Oncol. 2021 Apr 20. pii: S0090-8258(21)00327.
    PubMed     Abstract available


  468. THUSGAARD CF, Korsholm M, Koldby KM, Kruse TA, et al
    Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review.
    Gynecol Oncol. 2021 Apr 20. pii: S0090-8258(21)00330.
    PubMed     Abstract available


  469. SWAYZE EJ, Strzyzewski L, Avula P, Zebolsky AL, et al
    The impact of expanding gynecologic oncology care to ovarian cancer patients in small cities and rural communities.
    Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00331.
    PubMed     Abstract available


  470. MARTINEZ A, Buckley M, Scalise CB, Katre AA, et al
    Understanding the effect of mechanical forces on ovarian cancer progression.
    Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00273.
    PubMed     Abstract available


  471. ARTIOLI G, Giannone G, Valabrega G, Maggiorotto F, et al
    Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
    Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00324.
    PubMed     Abstract available


  472. DENG M, Wu D, Zhang Y, Jin Z, et al
    MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer.
    Gynecol Oncol. 2021 Apr 17. pii: S0090-8258(21)00323.
    PubMed     Abstract available


  473. SHIM SH, Chae SH, So KA, Lee SJ, et al
    Optimal duration of fertility-sparing hormonal treatment for early-stage endometrioid endometrial cancer.
    Gynecol Oncol. 2021 Apr 17. pii: S0090-8258(21)00270.
    PubMed     Abstract available


  474. GONZALEZ-BOSQUET J, Bakkum-Gamez JN, Weaver AL, McGree ME, et al
    PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00318.
    PubMed     Abstract available


  475. NITECKI R, Fleming ND, Fellman BM, Meyer LA, et al
    Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer.
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00322.
    PubMed     Abstract available


  476. LANDY R, Mathews C, Robertson M, Wiggins CL, et al
    Erratum to 'A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States' [Gynecologic Oncology 159 (2020) 344-353].
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00319.
    PubMed    


  477. GUPTA VG, Hirst J, Petersen S, Roby KF, et al
    Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00325.
    PubMed     Abstract available


  478. HUTTEN RJ, Huang YJ, Gaffney DK
    Stereotactic body radiotherapy for the treatment of gynecologic malignancies: Passing fancy or here to stay?
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00320.
    PubMed    


  479. TONE AA, McCuaig JM, Ricker N, Boghosian T, et al
    The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches.
    Gynecol Oncol. 2021 Apr 13. pii: S0090-8258(21)00321.
    PubMed     Abstract available


  480. VREDE SW, van Weelden WJ, Visser NCM, Bulten J, et al
    Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
    Gynecol Oncol. 2021 Apr 12. pii: S0090-8258(21)00269.
    PubMed     Abstract available


  481. FANG C, Zhang P, Yu A, Yang Y, et al
    Different prognosis of stage IIIB cervical cancer patients with lower third of vaginal invasion and those without.
    Gynecol Oncol. 2021 Apr 12. pii: S0090-8258(21)00275.
    PubMed     Abstract available


  482. VAN DE VORST REWM, Hoogendam JP, van der Aa MA, Witteveen PO, et al
    The attributive value of comprehensive surgical staging in clinically early-stage epithelial ovarian carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Apr 10. pii: S0090-8258(21)00317.
    PubMed     Abstract available


  483. FENG JL, Dixon-Suen SC, Jordan SJ, Webb PM, et al
    Is there sufficient evidence to recommend women diagnosed with endometrial cancer take a statin: Results from an Australian record-linkage study.
    Gynecol Oncol. 2021 Apr 9. pii: S0090-8258(21)00271.
    PubMed     Abstract available


  484. FLEMING ND, Westin SN, Rauh-Hain JA, Soliman PT, et al
    Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer.
    Gynecol Oncol. 2021 Apr 7. pii: S0090-8258(21)00272.
    PubMed     Abstract available


  485. JANDA M, Robledo KP, Gebski V, Armes JE, et al
    Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial.
    Gynecol Oncol. 2021;161:143-151.
    PubMed     Abstract available


  486. CHASE DM, Neighbors J, Perhanidis J, Monk BJ, et al
    Gastrointestinal symptoms and diagnosis preceding ovarian cancer diagnosis: Effects on treatment allocation and potential diagnostic delay.
    Gynecol Oncol. 2021 Apr 1. pii: S0090-8258(21)00259.
    PubMed     Abstract available


  487. DODD RH, Cvejic E, Bell K, Black K, et al
    Active surveillance as a management option for cervical intraepithelial neoplasia 2: An online experimental study.
    Gynecol Oncol. 2021;161:179-187.
    PubMed     Abstract available


  488. BOER FL, Ten Eikelder MLG, van Geloven N, Kapiteijn EH, et al
    Evaluation of treatment, prognostic factors, and survival in 198 vulvar melanoma patients: Implications for clinical practice.
    Gynecol Oncol. 2021;161:202-210.
    PubMed     Abstract available


  489. CRAMER DW, Vitonis AF, Sasamoto N, Yamamoto H, et al
    Epidemiologic and biologic correlates of serum HE4 and CA125 in women from the National Health and Nutritional Survey (NHANES).
    Gynecol Oncol. 2021;161:282-290.
    PubMed     Abstract available


  490. ASHMORE S, Crafton SM, Miller EM, Krivak TC, et al
    Optimal overall treatment time for adjuvant therapy for women with completely resected, node-positive vulvar cancer.
    Gynecol Oncol. 2021;161:63-69.
    PubMed     Abstract available


  491. JOU J, Zimmer Z, Charo L, Yau C, et al
    HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease.
    Gynecol Oncol. 2021;161:25-33.
    PubMed     Abstract available


    March 2021
  492. MALLEN A, Todd S, Robertson SE, Kim J, et al
    Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer.
    Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00228.
    PubMed     Abstract available


  493. RAFFONE A, Catena U, Travaglino A, Masciullo V, et al
    Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study.
    Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00267.
    PubMed     Abstract available


  494. GEOFFRON S, Lier A, de Kermadec E, Sermondade N, et al
    Fertility preservation in women with malignant and borderline ovarian tumors: Experience of the French ESGO-certified center and pregnancy-associated cancer network (CALG).
    Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00268.
    PubMed     Abstract available


  495. SIA TY, Huang Y, Gockley A, Melamed A, et al
    Trends in ovarian conservation and association with survival in premenopausal patients with stage I leiomyosarcoma.
    Gynecol Oncol. 2021 Mar 30. pii: S0090-8258(21)00265.
    PubMed     Abstract available


  496. GIL-MORENO A, Alonso-Alconada L, Diaz-Feijoo B, Domingo S, et al
    M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients.
    Gynecol Oncol. 2021 Mar 29. pii: S0090-8258(21)00260.
    PubMed     Abstract available


  497. HAN Y, Park IS, Kim SI, Wang W, et al
    Increasing serum gamma-glutamyltransferase level accompanies a rapid increase in the incidence of endometrial cancer in Korea: A nationwide cohort study.
    Gynecol Oncol. 2021 Mar 29. pii: S0090-8258(21)00262.
    PubMed     Abstract available


  498. RAHIMIAN N, Razavi ZS, Aslanbeigi F, Mirkhabbaz AM, et al
    Non-coding RNAs related to angiogenesis in gynecological cancer.
    Gynecol Oncol. 2021 Mar 26. pii: S0090-8258(21)00258.
    PubMed     Abstract available


  499. FALCONE F, Breda E, Ferrandina G, Malzoni M, et al
    Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database.
    Gynecol Oncol. 2021 Mar 26. pii: S0090-8258(21)00261.
    PubMed     Abstract available


  500. CARTMEL B, Hughes M, Ercolano EA, Gottlieb L, et al
    Randomized trial of exercise on depressive symptomatology and brain derived neurotrophic factor (BDNF) in ovarian cancer survivors: The Women's Activity and Lifestyle Study in Connecticut (WALC).
    Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00195.
    PubMed     Abstract available


  501. ZHANG X, Devins K, Ko EM, Reyes MC, et al
    Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.
    Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00257.
    PubMed     Abstract available


  502. FILIPPOVA OT, Tin AL, Alonso J, Vickers AJ, et al
    Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer.
    Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00252.
    PubMed     Abstract available


  503. WATSON CH, Puechl AM, Lim S, Monuszko K, et al
    Chemotherapy discontinuation processes in a gynecologic oncology population.
    Gynecol Oncol. 2021 Mar 23. pii: S0090-8258(21)00196.
    PubMed     Abstract available


  504. NASIOUDIS D, Byrne M, Ko EM, Giuntoli RL 2nd, et al
    Outcomes of sentinel lymph node mapping for patients with FIGO stage I endometrioid endometrial carcinoma.
    Gynecol Oncol. 2021 Mar 23. pii: S0090-8258(21)00256.
    PubMed     Abstract available


  505. MATSUO K, Huang Y, Matsuzaki S, Ragab OM, et al
    Association between definitive chemoradiotherapy wait-time and survival in locally-advanced cervical cancer: Implications during the coronavirus pandemic.
    Gynecol Oncol. 2021 Mar 23. pii: S0090-8258(21)00171.
    PubMed     Abstract available


  506. CHANG CL, Ho SC, Su YF, Juan YC, et al
    DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: Real-world evidence in Taiwan.
    Gynecol Oncol. 2021 Mar 20. pii: S0090-8258(21)00148.
    PubMed     Abstract available


  507. PEIRETTI M, Candotti G, Fais ML, Ricciardi E, et al
    Corrigendum to 'Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary' [Gynecologic Oncology 157 (2020) 85-88].
    Gynecol Oncol. 2021 Mar 20. pii: S0090-8258(21)00201.
    PubMed    


  508. KONECNY GE, Oza AM, Tinker AV, Oaknin A, et al
    Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
    Gynecol Oncol. 2021 Mar 19. pii: S0090-8258(21)00235.
    PubMed     Abstract available


  509. ALHOLM Z, Monk BJ, Ting J, Pulgar S, et al
    Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis.
    Gynecol Oncol. 2021 Mar 16. pii: S0090-8258(21)00194.
    PubMed     Abstract available


  510. SOLSKY I, Chen J, Rebbeck TR
    Corrigendum to "Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations" [Gynecologic Oncology 156 (2020) 363-376].
    Gynecol Oncol. 2021 Mar 14. pii: S0090-8258(21)00200.
    PubMed    


  511. MATSUO K, Klar M, Harter P, Miller H, et al
    Trends in peritoneal cytology evaluation at hysterectomy for endometrial cancer in the United States.
    Gynecol Oncol. 2021 Mar 13. pii: S0090-8258(21)00232.
    PubMed     Abstract available


  512. MONK BJ, Coleman RL, Herzog TJ, Moore KN, et al
    The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00230.
    PubMed     Abstract available


  513. LOREEN A, Polen-De C, Monk BJ, Jackson AL, et al
    The role of blinded independent radiologic review in ovarian cancer clinical trials: Discerning the value.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00176.
    PubMed    


  514. ABEL MK, Liao CI, Chan C, Lee D, et al
    Racial disparities in high-risk uterine cancer histologic subtypes: A United States Cancer Statistics study.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00197.
    PubMed     Abstract available


  515. HASSELGREN E, Hertzberg D, Camderman T, Bjorne H, et al
    Perioperative fluid balance and major postoperative complications in surgery for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00179.
    PubMed     Abstract available


  516. RAFFONE A, Travaglino A, Raimondo D, Boccellino MP, et al
    Tumor-infiltrating lymphocytes and POLE mutation in endometrial carcinoma.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00175.
    PubMed     Abstract available


  517. ROCCONI RP, Monk BJ, Walter A, Herzog TJ, et al
    Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
    Gynecol Oncol. 2021 Mar 11. pii: S0090-8258(21)00229.
    PubMed     Abstract available


  518. MORDEN CR, Farrell AC, Sliwowski M, Lichtensztejn Z, et al
    Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
    Gynecol Oncol. 2021 Mar 10. pii: S0090-8258(21)00199.
    PubMed     Abstract available


  519. COWAN R, Nobre SP, Pradhan N, Yasukawa M, et al
    Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers.
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00142.
    PubMed     Abstract available


  520. SANTORO A, Angelico G, Travaglino A, Raffone A, et al
    Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification.
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00174.
    PubMed     Abstract available


  521. POST CCB, Mens JWM, Haverkort MAD, Koppe F, et al
    Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making.
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00198.
    PubMed     Abstract available


  522. LAGO V, Montero B, Lopez S, Padilla-Iserte P, et al
    Ultrastaging protocol in sentinel lymph node for apparent early stage ovarian cancer.
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00193.
    PubMed     Abstract available


  523. BUECHEL ME, Enserro D, Burger RA, Brady MF, et al
    Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00177.
    PubMed     Abstract available


  524. TEOH D, Hill EK, Goldsberry W, Levine L, et al
    Overcoming the barriers to HPV vaccination in high-risk populations in the U.S.
    Gynecol Oncol. 2021 Mar 8. pii: S0090-8258(21)00083.
    PubMed    


  525. SCHNARR KL, Seow H, Elit LM, Pond GR, et al
    The use of imaging in endometrial cancer prior to potential surgery: Are guidelines being followed?
    Gynecol Oncol. 2021 Mar 6. pii: S0090-8258(21)00166.
    PubMed     Abstract available


  526. ULLRICH A, Gultekin M, Teguete I, Trimble EL, et al
    Gynecologic oncology on the global health agenda: A wake-up call.
    Gynecol Oncol. 2021 Mar 5. pii: S0090-8258(21)00178.
    PubMed    


  527. BACKES FJ, Felix AS, Plante M, Gregoire J, et al
    Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?
    Gynecol Oncol. 2021 Mar 4. pii: S0090-8258(21)00154.
    PubMed     Abstract available


  528. HUANG C, Lin X, He J, Liu N, et al
    Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2021 Mar 2. pii: S0090-8258(21)00169.
    PubMed     Abstract available


  529. FILIPPOVA OT, Selenica P, Pareja F, Vahdatinia M, et al
    Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
    Gynecol Oncol. 2021 Mar 2. pii: S0090-8258(21)00173.
    PubMed     Abstract available


  530. FELIX AS, Sherman ME
    Implications of the obesity epidemic for endometrial cancer risk, mortality, and survivorship.
    Gynecol Oncol. 2021;160:643-645.
    PubMed    


  531. AUBREY C, Saad N, Kobel M, Mattatall F, et al
    Implications for management of ovarian cancer in a transgender man: Impact of androgens and androgen receptor status.
    Gynecol Oncol. 2021 Mar 1. pii: S0090-8258(21)00158.
    PubMed     Abstract available


  532. KIM J, Cho Y, Kim N, Chung SY, et al
    Magnetic resonance imaging-based validation of the 2018 FIGO staging system in patients treated with definitive radiotherapy for locally advanced cervix cancer.
    Gynecol Oncol. 2021;160:735-741.
    PubMed     Abstract available


    February 2021
  533. BERNARD L, Kwon JS, Simpson AN, Ferguson SE, et al
    The levonorgestrel intrauterine system for prevention of endometrial cancer in women with obesity: A cost-effectiveness study.
    Gynecol Oncol. 2021 Feb 26. pii: S0090-8258(21)00165.
    PubMed     Abstract available


  534. MULLEN MM, McKinnish TR, Fiala MA, Zamorano AS, et al
    A deficit-accumulation frailty index predicts survival outcomes in patients with gynecologic malignancy.
    Gynecol Oncol. 2021 Feb 26. pii: S0090-8258(21)00172.
    PubMed     Abstract available


  535. SIA TY, Wen T, Cham S, Friedman AM, et al
    The effect of frailty on postoperative readmissions, morbidity, and mortality in endometrial Cancer surgery.
    Gynecol Oncol. 2021 Feb 24. pii: S0090-8258(21)00167.
    PubMed     Abstract available


  536. SCHRIER E, Xiong N, Thompson E, Poort H, et al
    Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors.
    Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00168.
    PubMed     Abstract available


  537. SJOQUIST KM, Espinoza D, Mileshkin L, Ananda S, et al
    REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
    Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00109.
    PubMed     Abstract available


  538. AREND RC, Monk BJ, Herzog TJ, Moore KN, et al
    Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum r
    Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00151.
    PubMed     Abstract available


  539. DA CRUZ PAULA A, DeLair DF, Ferrando L, Fix DJ, et al
    Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer.
    Gynecol Oncol. 2021 Feb 20. pii: S0090-8258(21)00152.
    PubMed     Abstract available


  540. SKORSTENGAARD M, Frederiksen ME, Baillet MV, Beau AB, et al
    Cervical cancer survivors and health care use: A Danish population-based register study.
    Gynecol Oncol. 2021 Feb 19. pii: S0090-8258(21)00139.
    PubMed     Abstract available


  541. KURTZ JE, Gebski V, Sukhin V, Carey M, et al
    Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
    Gynecol Oncol. 2021 Feb 18. pii: S0090-8258(21)00155.
    PubMed     Abstract available


  542. FABER MT, Sperling CD, Bennetsen AKK, Aalborg GL, et al
    A Danish nationwide study of risk factors associated with Type I and Type II endometrial cancer.
    Gynecol Oncol. 2021 Feb 16. pii: S0090-8258(21)00147.
    PubMed     Abstract available


  543. FRIEDLANDER M, Benson C, O'Connell RL, Reed N, et al
    Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903).
    Gynecol Oncol. 2021 Feb 16. pii: S0090-8258(21)00153.
    PubMed     Abstract available


  544. INCI MG, Anders L, Woopen H, Richter R, et al
    Frailty Index for prediction of surgical outcome in ovarian cancer: Results of a prospective study.
    Gynecol Oncol. 2021 Feb 16. pii: S0090-8258(21)00149.
    PubMed     Abstract available


  545. LUO LY, Aviki EM, Lee A, Kollmeier MA, et al
    Socioeconomic inequality and omission of adjuvant radiation therapy in high-risk, early-stage endometrial cancer.
    Gynecol Oncol. 2021 Feb 14. pii: S0090-8258(21)00101.
    PubMed     Abstract available


  546. HICKEY M, Moss KM, Brand A, Wrede CD, et al
    What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    Gynecol Oncol. 2021 Feb 11. pii: S0090-8258(21)00108.
    PubMed     Abstract available


  547. BAANDRUP L, Dehlendorff C, Hertzum-Larsen R, Hannibal CG, et al
    Prognostic impact of socioeconomic status on long-term survival of non-localized epithelial ovarian cancer The Extreme study.
    Gynecol Oncol. 2021 Feb 11. pii: S0090-8258(21)00102.
    PubMed     Abstract available


  548. BURG LC, Vermeulen RJ, Bekkers RLM, Wijn SRW, et al
    A cost-effectiveness analysis of three approaches for lymph node assessment in patients with low- and intermediate-risk endometrial cancer.
    Gynecol Oncol. 2021 Feb 10. pii: S0090-8258(21)00095.
    PubMed     Abstract available


  549. DAHM-KAHLER P, Holmberg E, Holtenman M, Radestad AF, et al
    Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.
    Gynecol Oncol. 2021 Feb 10. pii: S0090-8258(21)00059.
    PubMed     Abstract available


  550. HASHEMIPOUR M, Boroumand H, Mollazadeh S, Tajiknia V, et al
    Exosomal microRNAs and exosomal long non-coding RNAs in gynecologic cancers.
    Gynecol Oncol. 2021 Feb 10. pii: S0090-8258(21)00140.
    PubMed     Abstract available


  551. INSIN P, Vitoopinyoparb K, Thadanipon K, Charakorn C, et al
    Prevention of venous thromboembolism in gynecological cancer patients undergoing major abdominopelvic surgery: A systematic review and network meta-analysis.
    Gynecol Oncol. 2021 Feb 6. pii: S0090-8258(21)00087.
    PubMed     Abstract available


  552. VARELA CAGETTI L, Gonzague-Casabianca L, Zemmour C, Lambaudie E, et al
    The impact of modern preoperative high-dose-rate brachytherapy in early-stage cervical cancer.
    Gynecol Oncol. 2021 Feb 6. pii: S0090-8258(21)00094.
    PubMed     Abstract available


  553. SIEDEL JH, Ring KL, Hu W, Dood RL, et al
    Clinical significance of homologous recombination deficiency score testing in endometrial Cancer.
    Gynecol Oncol. 2021 Feb 6. pii: S0090-8258(20)34181.
    PubMed     Abstract available


  554. COHEN PA, Powell A, Bohm S, Gilks CB, et al
    Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" Gynecol. Oncol. 154 (2019) 441-448.
    Gynecol Oncol. 2021 Feb 5. pii: S0090-8258(21)00092.
    PubMed    


  555. LATIF N, Oh J, Brensinger C, Morgan M, et al
    Lymphadenectomy is associated with an increased risk of postoperative venous thromboembolism in early stage endometrial cancer.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00090.
    PubMed     Abstract available


  556. CHAMBERS LM, Yao M, Morton M, Gruner M, et al
    Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00099.
    PubMed     Abstract available


  557. GU B, Shang X, Yan M, Li X, et al
    Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00096.
    PubMed     Abstract available


  558. RAHIMY E, Usoz M, von Eyben R, Fujimoto D, et al
    Phase II trial evaluating efficacy of a Fitbit program for improving the health of endometrial cancer survivors.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00093.
    PubMed     Abstract available


  559. ESSELEN KM, Stack-Dunnbier H, Gompers A, Hacker MR, et al
    Crowdsourcing to measure financial toxicity in gynecologic oncology.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00100.
    PubMed     Abstract available


  560. COLEMAN RL, Hu W, Soliman P, Nick A, et al
    Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00082.
    PubMed     Abstract available


  561. TAKENAKA M, Kamii M, Iida Y, Yanaihara N, et al
    Re-thinking the prognostic significance of positive peritoneal cytology in endometrial cancer.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00054.
    PubMed     Abstract available


  562. KUROKI LM, Morris DH, Greenwade M, Landon M, et al
    Impact of employment and insurance status on distress in gynecologic oncology patients.
    Gynecol Oncol. 2021 Feb 2. pii: S0090-8258(21)00098.
    PubMed     Abstract available


  563. LIU S, Kasherman L, Fazelzad R, Wang L, et al
    The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Feb 2. pii: S0090-8258(21)00088.
    PubMed     Abstract available


  564. LESLIE KK, Filiaci VL, Mallen AR, Thiel KW, et al
    Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
    Gynecol Oncol. 2021 Feb 1. pii: S0090-8258(21)00085.
    PubMed     Abstract available


  565. BROOKS SE, Davis EC, Farley JH
    Disparities in pap smear screening follow up: A catalyst for collective action vs. collective despair.
    Gynecol Oncol. 2021;160:361-363.
    PubMed    


    January 2021
  566. WANG XS, Kamal M, Chen TH, Shi Q, et al
    Assessment of physical function by subjective and objective methods in patients undergoing open gynecologic surgery.
    Gynecol Oncol. 2021 Jan 31. pii: S0090-8258(21)00081.
    PubMed     Abstract available


  567. HARRISON RF, Cantor SB, Sun CC, Villanueva M, et al
    Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.
    Gynecol Oncol. 2021 Jan 31. pii: S0090-8258(21)00084.
    PubMed     Abstract available


  568. MCGINNIS JM, Jones R, Hillis C, Kokus H, et al
    A pneumococcal pneumonia and influenza vaccination quality improvement program for women receiving chemotherapy for gynecologic cancers at a major tertiary cancer Centre.
    Gynecol Oncol. 2021 Jan 29. pii: S0090-8258(21)00061.
    PubMed     Abstract available


  569. HAMILTON CA, Pothuri B, Arend RC, Backes FJ, et al
    Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations.
    Gynecol Oncol. 2021 Jan 27. pii: S0090-8258(20)34224.
    PubMed     Abstract available


  570. PIZZOFERRATO AC, Klein M, Fauvet R, Durand C, et al
    Pelvic floor disorders and sexuality in women with ovarian cancer: A systematic review.
    Gynecol Oncol. 2021 Jan 27. pii: S0090-8258(21)00086.
    PubMed     Abstract available


  571. TOZZI R, Traill Z, Valenti G, Ferrari F, et al
    A prospective study on the diagnostic pathway of patients with stage IIIC-IV ovarian cancer: Exploratory laparoscopy (EXL) + CT scan VS. CT scan.
    Gynecol Oncol. 2021 Jan 26. pii: S0090-8258(21)00060.
    PubMed     Abstract available


  572. EOH KJ, Han M, Kim EH, Jung I, et al
    Markedly increased risk of malignancies in women with endometriosis.
    Gynecol Oncol. 2021 Jan 26. pii: S0090-8258(21)00079.
    PubMed     Abstract available


  573. BOGANI G, Sopracordevole F, Di Donato V, Ciavattini A, et al
    High-risk HPV-positive and -negative high-grade cervical dysplasia: Analysis of 5-year outcomes.
    Gynecol Oncol. 2021 Jan 26. pii: S0090-8258(21)00080.
    PubMed     Abstract available


  574. CHAMBERS LM, Michener CM, Rose PG, Reizes O, et al
    Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancer.
    Gynecol Oncol. 2021 Jan 24. pii: S0090-8258(21)00075.
    PubMed     Abstract available


  575. BOGANI G, Papadia A, Buda A, Casarin J, et al
    Sentinel node mapping vs. sentinel node mapping plus back-up lymphadenectomy in high-risk endometrial cancer patients: Results from a multi-institutional study.
    Gynecol Oncol. 2021 Jan 20. pii: S0090-8258(21)00055.
    PubMed     Abstract available


  576. CHASE DM, Salani R, Farley J, Torres T, et al
    Unwittingly biased: A note to gynecologic cancer providers.
    Gynecol Oncol. 2021 Jan 20. pii: S0090-8258(21)00056.
    PubMed    


  577. KIM SR, Tone A, Kim RH, Cesari M, et al
    Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study.
    Gynecol Oncol. 2021 Jan 18. pii: S0090-8258(21)00002.
    PubMed     Abstract available


  578. CHICHURA A, Chambers LM, Costales AB, Yao M, et al
    Impact of intra-operative factors upon peri-operative outcomes in women undergoing hyperthermic intraperitoneal chemotherapy for gynecologic cancer.
    Gynecol Oncol. 2021 Jan 16. pii: S0090-8258(21)00053.
    PubMed     Abstract available


  579. NOVIKOVA OV, Nosov VB, Panov VA, Novikova EG, et al
    Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
    Gynecol Oncol. 2021 Jan 15. pii: S0090-8258(21)00001.
    PubMed     Abstract available


  580. CASTLE PE, Locke A, Tergas AI, Befano B, et al
    The relationship of human papillomavirus and cytology co-testing results with endometrial and ovarian cancer diagnoses.
    Gynecol Oncol. 2021 Jan 13. pii: S0090-8258(21)00052.
    PubMed     Abstract available


  581. SCHEEPERS ERM, de Rooij BH, Pijnenborg JMA, van Huis-Tanja LH, et al
    Perceived social support in patients with endometrial or ovarian cancer: A secondary analysis from the ROGY care study.
    Gynecol Oncol. 2021 Jan 13. pii: S0090-8258(20)34246.
    PubMed     Abstract available


  582. KALJOUW S, Jansen EEL, Aitken CA, Harrijvan LM, et al
    Reducing unnecessary referrals for colposcopy in hrHPV-positive women within the Dutch cervical cancer screening programme: A modelling study.
    Gynecol Oncol. 2021 Jan 12. pii: S0090-8258(20)34253.
    PubMed     Abstract available


  583. HAMILTON CA, Pothuri B, Arend RC, Backes FJ, et al
    Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II.
    Gynecol Oncol. 2021 Jan 12. pii: S0090-8258(20)34227.
    PubMed     Abstract available


  584. BILBAO M, Aikins JK, Ostrovsky O
    Is routine omentectomy of grossly normal omentum helpful in surgery for ovarian cancer? A look at the tumor microenvironment and its clinical implications.
    Gynecol Oncol. 2021 Jan 9. pii: S0090-8258(20)34248.
    PubMed     Abstract available


  585. KO EM, Aviles D, Koelper NC, Morgan MA, et al
    Impact of past surgical history on perioperative outcomes in gynecologic surgery.
    Gynecol Oncol. 2021 Jan 9. pii: S0090-8258(20)34241.
    PubMed     Abstract available


  586. HAGEMANN IS, Deng W, Zaino RJ, Powell MA, et al
    The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women.
    Gynecol Oncol. 2021 Jan 7. pii: S0090-8258(20)34255.
    PubMed     Abstract available


  587. KANAO H, Aoki Y, Omi M, Nomura H, et al
    Laparoscopic pelvic exenteration and laterally extended endopelvic resection for postradiation recurrent cervical carcinoma: Technical feasibility and short-term oncologic outcome.
    Gynecol Oncol. 2021 Jan 7. pii: S0090-8258(20)34249.
    PubMed     Abstract available


  588. LEES B, Hampton JM, Trentham-Dietz A, Newcomb P, et al
    A population-based study of causes of death after endometrial cancer according to major risk factors.
    Gynecol Oncol. 2021 Jan 6. pii: S0090-8258(20)34223.
    PubMed     Abstract available


  589. MATSUZAKI S, Matsuzaki S, Chang EJ, Yasukawa M, et al
    Surgical and oncologic outcomes of hyperthermic intraperitoneal chemotherapy for uterine leiomyosarcoma: A systematic review of literature.
    Gynecol Oncol. 2021 Jan 5. pii: S0090-8258(20)34247.
    PubMed     Abstract available


  590. DELLINGER TH, Han ES
    State of the Science: The role of HIPEC in the treatment of ovarian cancer.
    Gynecol Oncol. 2021 Jan 5. pii: S0090-8258(20)34243.
    PubMed    


  591. ZAPARDIEL I, Kocian R, Kohler C, Klat J, et al
    Voiding recovery after radical parametrectomy in cervical cancer patients: An international prospective multicentre trial - SENTIX.
    Gynecol Oncol. 2021 Jan 5. pii: S0090-8258(20)34221.
    PubMed     Abstract available


  592. TJALSMA AS, Wagner A, Dinjens WNM, Ewing-Graham PC, et al
    Evaluation of a nationwide Dutch guideline to detect Lynch syndrome in patients with endometrial cancer.
    Gynecol Oncol. 2021 Jan 5. pii: S0090-8258(20)34242.
    PubMed     Abstract available


  593. DI DONATO V, Caruso G, Bogani G, Giannini A, et al
    Preoperative frailty assessment in patients undergoing gynecologic oncology surgery: A systematic review.
    Gynecol Oncol. 2021 Jan 4. pii: S0090-8258(20)34245.
    PubMed     Abstract available


  594. MATSUO K, Matsuzaki S, Mandelbaum RS, Kanao H, et al
    Utilization and perioperative outcome of minimally invasive pelvic exenteration in gynecologic malignancies: A national study in the United States.
    Gynecol Oncol. 2021 Jan 2. pii: S0090-8258(20)34251.
    PubMed     Abstract available


  595. BATMAN S, Bohn J, Weisenberger MW, Hersh A, et al
    Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis.
    Gynecol Oncol. 2021;160:214-218.
    PubMed     Abstract available


  596. HEUS C, Smorenburg A, Stoker J, Rutten MJ, et al
    Visceral obesity and muscle mass determined by CT scan and surgical outcome in patients with advanced ovarian cancer. A retrospective cohort study.
    Gynecol Oncol. 2021;160:187-192.
    PubMed     Abstract available


  597. SPINOSA D, Acosta T, Wong J, Kurtovic K, et al
    Universal screening for Lynch syndrome in uterine cancer patients: A quality improvement initiative.
    Gynecol Oncol. 2021;160:169-174.
    PubMed     Abstract available


  598. HAMPEL H, Pearlman R, de la Chapelle A, Pritchard CC, et al
    Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients.
    Gynecol Oncol. 2021;160:161-168.
    PubMed     Abstract available


  599. SHALOWITZ DI
    Physician outreach and access to gynecologic cancer care.
    Gynecol Oncol. 2021;160:1-2.
    PubMed    


  600. GOODMAN CD, Mendez LC, Velker V, Weiss Y, et al
    3D image-guided interstitial brachytherapy for primary vaginal cancer: A multi-institutional experience.
    Gynecol Oncol. 2021;160:134-139.
    PubMed     Abstract available


  601. ALIMENA S, Sullivan MW, Philp L, Dorney K, et al
    Patient reported outcome measures among patients with vulvar cancer at various stages of treatment, recurrence, and survivorship.
    Gynecol Oncol. 2021;160:252-259.
    PubMed     Abstract available


  602. FADADU PP, Polen-De CL, McGree ME, Weaver AL, et al
    Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation.
    Gynecol Oncol. 2021;160:40-44.
    PubMed     Abstract available


  603. VAN DER VELDEN J, Pleunis N, Barlow E, Zijlmans H, et al
    Radiotherapy is not indicated in patients with vulvar squamous cell carcinoma and only one occult intracapsular groin node metastasis.
    Gynecol Oncol. 2021;160:128-133.
    PubMed     Abstract available


  604. INAYAMA Y, Yamanishi Y, Nakatani E, Aratake J, et al
    Imiquimod for vaginal intraepithelial neoplasia 2-3: A systematic review and meta-analysis.
    Gynecol Oncol. 2021;160:140-147.
    PubMed     Abstract available


  605. BOGANI G, Raspagliesi F, di Donato V, Brusadelli C, et al
    Spotlight on the role of human papillomavirus vaccines.
    Gynecol Oncol. 2021;160:346-350.
    PubMed     Abstract available


    December 2020
  606. DAHLMAN D, Li X, Magnusson H, Sundquist J, et al
    Cervical cancer among Swedish women with drug use disorders: A nationwide epidemiological study.
    Gynecol Oncol. 2020 Dec 31. pii: S0090-8258(20)34214.
    PubMed     Abstract available


  607. DUSKA LR, Krasner CN, O'Malley DM, Hays JL, et al
    A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Gynecol Oncol. 2020 Dec 31. pii: S0090-8258(20)34228.
    PubMed     Abstract available


  608. MOYNAGH MR, Dowdy SC, Welch B, Glaser GE, et al
    Image-guided tumor ablation in gynecologic oncology: Review of interventional oncology techniques and case examples highlighting a collaborative, multidisciplinary program.
    Gynecol Oncol. 2020 Dec 30. pii: S0090-8258(20)34252.
    PubMed     Abstract available


  609. BISCH SP, Jago CA, Kalogera E, Ganshorn H, et al
    Outcomes of enhanced recovery after surgery (ERAS) in gynecologic oncology - A systematic review and meta-analysis.
    Gynecol Oncol. 2020 Dec 30. pii: S0090-8258(20)34250.
    PubMed     Abstract available


  610. BOERNER T, Walch HS, Nguyen B, Iasonos A, et al
    Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study.
    Gynecol Oncol. 2020 Dec 29. pii: S0090-8258(20)34225.
    PubMed     Abstract available


  611. MATSUO K, Nishio S, Matsuzaki S, Iwase H, et al
    Surgical margin status and recurrence pattern in invasive vulvar Paget's disease: A Japanese Gynecologic Oncology Group study.
    Gynecol Oncol. 2020 Dec 28. pii: S0090-8258(20)34226.
    PubMed     Abstract available


  612. MESSELT A, Thomaier L, Jewett PI, Lee H, et al
    Comparisons of emotional health by diagnosis among women with early stage gynecological cancers.
    Gynecol Oncol. 2020 Dec 28. pii: S0090-8258(20)34222.
    PubMed     Abstract available


  613. LIANG MI, Chen L, Hershman DL, Hillyer GC, et al
    Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
    Gynecol Oncol. 2020 Dec 27. pii: S0090-8258(20)34218.
    PubMed     Abstract available


  614. GHEZELAYAGH TS, Pennington KP, Norquist BM, Khasnavis N, et al
    Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
    Gynecol Oncol. 2020 Dec 26. pii: S0090-8258(20)34178.
    PubMed     Abstract available


  615. BERGER AA, Dao F, Levine DA
    Angiogenesis in endometrial carcinoma: Therapies and biomarkers, current options, and future perspectives.
    Gynecol Oncol. 2020 Dec 26. pii: S0090-8258(20)34219.
    PubMed     Abstract available


  616. AYHAN A, Toptas T, Oz M, Vardar MA, et al
    Low-grade endometrial stromal sarcoma: A Turkish uterine sarcoma group study analyzing prognostic factors and disease outcomes.
    Gynecol Oncol. 2020 Dec 26. pii: S0090-8258(20)34220.
    PubMed     Abstract available


  617. CASTELLANO T, John Maxwell IV, Adam Walter J, Thompson S, et al
    Phase II trial of vaginal cuff brachytherapy followed by dose-dense chemotherapy in early stage endometrial cancer patients with enriched, high-intermediate risk factors for recurrence.
    Gynecol Oncol. 2020 Dec 23. pii: S0090-8258(20)34217.
    PubMed     Abstract available


  618. PHILP L, Tannenbaum S, Haber H, Saini A, et al
    Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer.
    Gynecol Oncol. 2020 Dec 23. pii: S0090-8258(20)34174.
    PubMed     Abstract available


  619. GUO Y, Jiang T, Ouyang L, Li X, et al
    A novel diagnostic nomogram based on serological and ultrasound findings for preoperative prediction of malignancy in patients with ovarian masses.
    Gynecol Oncol. 2020 Dec 20. pii: S0090-8258(20)34177.
    PubMed     Abstract available


  620. JOU J, Coulter E, Roberts T, Binder P, et al
    Assessment of malnutrition by unintentional weight loss and its implications on oncologic outcomes in patient with locally advanced cervical cancer receiving primary chemoradiation.
    Gynecol Oncol. 2020 Dec 17. pii: S0090-8258(20)34180.
    PubMed     Abstract available


  621. BANVILLE AC, Wouters MCA, Oberg AL, Goergen KM, et al
    Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
    Gynecol Oncol. 2020 Dec 17. pii: S0090-8258(20)34176.
    PubMed     Abstract available


  622. FACHINI AMD, Zuliani AC, Sarian LO, Teixeira JC, et al
    Long-term outcomes of concomitant cisplatin plus radiotherapy versus radiotherapy alone in patients with stage IIIB squamous cervical cancer: A randomized controlled trial.
    Gynecol Oncol. 2020 Dec 16. pii: S0090-8258(20)34157.
    PubMed     Abstract available


  623. LEUNG E, Pervaiz Z, Lowe-Zinola J, Cree S, et al
    Maintaining surgical care delivery during the COVID-19 pandemic: A comparative cohort study at a tertiary gynecological cancer centre.
    Gynecol Oncol. 2020 Dec 16. pii: S0090-8258(20)34216.
    PubMed     Abstract available


  624. KARNEZIS AN, Chen SY, Chow C, Yang W, et al
    Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines.
    Gynecol Oncol. 2020 Dec 13. pii: S0090-8258(20)34175.
    PubMed     Abstract available


  625. FORD S, Tarraf W, Williams KP, Roman LA, et al
    Differences in cervical cancer screening and follow-up for black and white women in the United States.
    Gynecol Oncol. 2020 Dec 12. pii: S0090-8258(20)34155.
    PubMed     Abstract available


  626. FORSSE D, Berg HF, Bozickovic O, Engerud H, et al
    Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer.
    Gynecol Oncol. 2020 Dec 11. pii: S0090-8258(20)34173.
    PubMed     Abstract available


  627. YUE H, Li W, Chen R, Wang J, et al
    Stromal POSTN induced by TGF-beta1 facilitates the migration and invasion of ovarian cancer.
    Gynecol Oncol. 2020 Dec 11. pii: S0090-8258(20)34154.
    PubMed     Abstract available


  628. COLLINS A, Miles GJ, Powley IR, Hew R, et al
    Development of a patient-derived explant model for prediction of drug responses in endometrial cancer.
    Gynecol Oncol. 2020 Dec 10. pii: S0090-8258(20)34161.
    PubMed     Abstract available


  629. SOBECKI JN, Rice LW, Hartenbach EM
    Bone health and osteoporosis screening in gynecologic cancer survivors.
    Gynecol Oncol. 2020 Dec 10. pii: S0090-8258(20)34156.
    PubMed     Abstract available


  630. NAHSHON C, Segev Y, Gemer O, Bar Noy T, et al
    Should the risk for uterine cancer influence decision making for prophylactic hysterectomy in BRCA1/2 mutated patients- a systematic review and meta-analysis.
    Gynecol Oncol. 2020 Dec 9. pii: S0090-8258(20)34162.
    PubMed     Abstract available


  631. GOTOH O, Kiyotani K, Chiba T, Sugiyama Y, et al
    Immunogenomic landscape of gynecologic carcinosarcoma.
    Gynecol Oncol. 2020 Dec 6. pii: S0090-8258(20)34158.
    PubMed     Abstract available


  632. CAIN KE, Iniesta MD, Fellman BM, Suki TS, et al
    Effect of preoperative intravenous vs oral acetaminophen on postoperative opioid consumption in an enhanced recovery after surgery (ERAS) program in patients undergoing open gynecologic oncology surgery.
    Gynecol Oncol. 2020 Dec 6. pii: S0090-8258(20)34152.
    PubMed     Abstract available


  633. PAREEK V, Barthwal M, Giridhar P, Patil PA, et al
    A phase III randomised trial of trans-abdominal ultrasound in improving application quality and dosimetry of intra-cavitary brachytherapy in locally advanced cervical cancer.
    Gynecol Oncol. 2020 Dec 6. pii: S0090-8258(20)34160.
    PubMed     Abstract available


  634. APPIAH D, Farias RM, Olokede OA, Nwabuo CC, et al
    The influence of individual and neighborhood-level characteristics on rural-urban disparities in cardiovascular disease mortality among U.S. women diagnosed with breast and gynecologic cancers.
    Gynecol Oncol. 2020 Dec 6. pii: S0090-8258(20)34151.
    PubMed     Abstract available


  635. NGO NT, Aniagolu N, Lang J, Mcdougale A, et al
    Underrepresented minority representation trends in gynecologic oncology fellowships in the United States.
    Gynecol Oncol. 2020 Dec 1. pii: S0090-8258(20)34130.
    PubMed     Abstract available


  636. TRAVAGLINO A, Raffone A, Gencarelli A, Saracinelli S, et al
    Clinico-pathological features associated with mismatch repair deficiency in endometrial undifferentiated/dedifferentiated carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 Dec 1. pii: S0090-8258(20)34126.
    PubMed     Abstract available


  637. ISLAM JY, Deveaux A, Previs RA, Akinyemiju T, et al
    Racial and ethnic disparities in palliative care utilization among gynecological cancer patients.
    Gynecol Oncol. 2020 Dec 1. pii: S0090-8258(20)34159.
    PubMed     Abstract available


  638. COHEN JG, Chang AJ
    Use of stereotactic body radiotherapy in gynecologic cancers: Local control with systemic treatment implications.
    Gynecol Oncol. 2020;159:599-600.
    PubMed    


  639. DEKEN MM, van Doorn HC, Verver D, Boogerd LSF, et al
    Near-infrared fluorescence imaging compared to standard sentinel lymph node detection with blue dye in patients with vulvar cancer - a randomized controlled trial.
    Gynecol Oncol. 2020;159:672-680.
    PubMed     Abstract available


  640. SPINILLO A, Dominoni M, Boschi AC, Cesari S, et al
    The relationship of human papillomavirus infection with endocervical glandular involvement on cone specimens in women with cervical intraepithelial neoplasia.
    Gynecol Oncol. 2020;159:630-635.
    PubMed     Abstract available


  641. COHEN PA, Leung Y, Anderson L, van der Griend R, et al
    Excisional treatment comparison for in situ endocervical adenocarcinoma (EXCISE): A phase 2 pilot randomized controlled trial to compare histopathological margin status, specimen size and fragmentation after loop electrosurgical excision procedure and
    Gynecol Oncol. 2020;159:623-629.
    PubMed     Abstract available


  642. HELLMAN K, Holmberg E, Bjurberg M, Borgfeldt C, et al
    Primary treatment and relative survival by stage and age in vulvar squamous cell carcinoma: A population-based SweGCG study.
    Gynecol Oncol. 2020;159:663-671.
    PubMed     Abstract available


  643. RICHMAN AH, Vargo JA, Ling DC, Sukumvanich P, et al
    Dose-escalated intensity modulated radiation therapy in patients with locally-advanced vulvar cancer - does it increase response rate?
    Gynecol Oncol. 2020;159:657-662.
    PubMed     Abstract available


  644. BOGANI G, DI Donato V, Sopracordevole F, Ciavattini A, et al
    Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study.
    Gynecol Oncol. 2020;159:636-641.
    PubMed     Abstract available


  645. STOVER EH, Fuh K, Konstantinopoulos PA, Matulonis UA, et al
    Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Gynecol Oncol. 2020;159:887-898.
    PubMed     Abstract available


  646. WANG Z, Yin P, Sun Y, Na L, et al
    LGR4 maintains HGSOC cell epithelial phenotype and stem-like traits.
    Gynecol Oncol. 2020;159:839-849.
    PubMed     Abstract available


  647. FUH K, Mullen M, Blachut B, Stover E, et al
    Homologous recombination deficiency real-time clinical assays, ready or not?
    Gynecol Oncol. 2020;159:877-886.
    PubMed     Abstract available


  648. VETTER MH, Castaneda A, Khan A, O'Malley DM, et al
    A clinical classification system for grading platinum hypersensitivity reactions.
    Gynecol Oncol. 2020;159:794-798.
    PubMed     Abstract available


    November 2020
  649. STRAUBHAR AM, Wolf JL, Zhou MQC, Iasonos A, et al
    Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events.
    Gynecol Oncol. 2020 Nov 30. pii: S0090-8258(20)34132.
    PubMed     Abstract available


  650. SUGRUE R, Foley O, Elias KM, Growdon WB, et al
    Outcomes of minimally invasive versus open abdominal hysterectomy in patients with gestational trophoblastic disease.
    Gynecol Oncol. 2020 Nov 30. pii: S0090-8258(20)34150.
    PubMed     Abstract available


  651. GRESSEL GM, Marcus JZ, Mullen MM, Sinno AK, et al
    Direct oral anticoagulant use in gynecologic oncology: A Society of Gynecologic Oncology Clinical Practice Statement.
    Gynecol Oncol. 2020 Nov 28. pii: S0090-8258(20)34131.
    PubMed     Abstract available


  652. HULSTAERT E, Morlion A, Levanon K, Vandesompele J, et al
    Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer: A systematic review.
    Gynecol Oncol. 2020 Nov 27. pii: S0090-8258(20)34129.
    PubMed     Abstract available


  653. WU L, Zhu J, Yin R, Wu X, et al
    Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort.
    Gynecol Oncol. 2020 Nov 26. pii: S0090-8258(20)34013.
    PubMed     Abstract available


  654. CHO A, Lee SW, Park JY, Kim DY, et al
    Continued medical treatment for persistent early endometrial cancer in young women.
    Gynecol Oncol. 2020 Nov 24. pii: S0090-8258(20)34115.
    PubMed     Abstract available


  655. CONSIDINE DPC, Jia G, Shu X, Schildkraut JM, et al
    Genetically predicted circulating protein biomarkers and ovarian cancer risk.
    Gynecol Oncol. 2020 Nov 24. pii: S0090-8258(20)34127.
    PubMed     Abstract available


  656. CHELARIU-RAICU A, Nick A, Urban R, Gordinier M, et al
    A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer.
    Gynecol Oncol. 2020 Nov 23. pii: S0090-8258(20)34124.
    PubMed     Abstract available


  657. HICKS-COURANT K, Kanter GP, Giuntoli RL 2nd, Schapira MM, et al
    An increase in multi-site practices: The shifting paradigm for gynecologic cancer care delivery.
    Gynecol Oncol. 2020 Nov 23. pii: S0090-8258(20)34052.
    PubMed     Abstract available


  658. KHATIB G, Seyfettinoglu S, Guzel AB, Gulec UK, et al
    Feasibility and rationale of a novel approach in advanced ovarian cancer surgery: Bat- shaped en-bloc total peritonectomy and total hysterectomy salpingo-oophorectomy with or without rectosigmoid resection (Sarta-Bat approach).
    Gynecol Oncol. 2020 Nov 21. pii: S0090-8258(20)34122.
    PubMed     Abstract available


  659. FEJZO MS, Chen HW, Anderson L, McDermott MS, et al
    Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
    Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34116.
    PubMed     Abstract available


  660. MORSE CB, Voillet V, Bates BM, Chiu EY, et al
    Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease.
    Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34117.
    PubMed     Abstract available


  661. RANA HQ, Kipnis L, Hehir K, Cronin A, et al
    Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer.
    Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34111.
    PubMed     Abstract available


  662. FREY MK, Chapman-Davis E, Glynn SM, Lin J, et al
    Adapting and avoiding coping strategies for women with ovarian cancer during the COVID-19 pandemic.
    Gynecol Oncol. 2020 Nov 19. pii: S0090-8258(20)34128.
    PubMed     Abstract available


  663. RODRIGUEZ AM, Polychronopoulou E, Hsu E, Shah R, et al
    Factors associated with endometrial cancer and hyperplasia among middle-aged and older Hispanics.
    Gynecol Oncol. 2020 Nov 18. pii: S0090-8258(20)34055.
    PubMed     Abstract available


  664. CHAMBERS LM, Jia X, Rose PG, AlHilli M, et al
    Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysis.
    Gynecol Oncol. 2020 Nov 18. pii: S0090-8258(20)34123.
    PubMed     Abstract available


  665. XU Y, Jia Y, Zhang Q, Du Y, et al
    Incidence and risk factors for postoperative venous thromboembolism in patients with ovarian cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2020 Nov 18. pii: S0090-8258(20)34121.
    PubMed     Abstract available


  666. WEEKS K, Lynch CF, West M, Carnahan R, et al
    Rural disparities in surgical care from gynecologic oncologists among Midwestern ovarian cancer patients.
    Gynecol Oncol. 2020 Nov 17. pii: S0090-8258(20)34114.
    PubMed     Abstract available


  667. AYHAN A, Oz M, Topfedaisi Ozkan N, Aslan K, et al
    Perioperative SARS-CoV-2 infection among women undergoing major gynecologic cancer surgery in the COVID-19 era: A nationwide, cohort study from Turkey.
    Gynecol Oncol. 2020 Nov 17. pii: S0090-8258(20)34125.
    PubMed     Abstract available


  668. STALEY SA, Tucker KR, Gehrig PA, Clark LH, et al
    Accuracy of preoperative cross-sectional imaging in cervical cancer patients undergoing primary radical surgery.
    Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34067.
    PubMed     Abstract available


  669. BOERNER T, Tanner E, Filippova O, Zhou QC, et al
    Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34064.
    PubMed     Abstract available


  670. HOEIJMAKERS YM, Gorris MAJ, Sweep FCGJ, Bulten J, et al
    Immune cell composition in the endometrium of patients with a complete molar pregnancy: Effects on outcome.
    Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34113.
    PubMed     Abstract available


  671. O'TOOLE SA, Huang Y, Norris L, Power Foley M, et al
    HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status.
    Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34112.
    PubMed     Abstract available


  672. CHEN F, Bailey CE, Alvarez RD, Shu XO, et al
    Adherence to treatment guidelines as a major determinant of survival disparities between black and white patients with ovarian cancer.
    Gynecol Oncol. 2020 Nov 15. pii: S0090-8258(20)34062.
    PubMed     Abstract available


  673. JANSEN EEL, Ivanus U, Jerman T, de Koning HJ, et al
    The optimal HPV-screening protocol in Eastern-Europe: The example of Slovenia.
    Gynecol Oncol. 2020 Nov 13. pii: S0090-8258(20)34058.
    PubMed     Abstract available


  674. KIMBLE DC, Dvergsten E, Thomeas-McEwing V, Karovic S, et al
    Evaluation of publicly available in vitro drug sensitivity models for ovarian and uterine cancer.
    Gynecol Oncol. 2020 Nov 12. pii: S0090-8258(20)34066.
    PubMed     Abstract available


  675. POORT H, Fenton ATHR, Thompson E, Dinardo MM, et al
    Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study.
    Gynecol Oncol. 2020 Nov 12. pii: S0090-8258(20)34056.
    PubMed     Abstract available


  676. GUO XM, Cowan M, Folsom S, Ehimiaghe E, et al
    Discrepancies between author- and industry-reported disclosures of financial relationships at an annual gynecologic oncology research meeting.
    Gynecol Oncol. 2020 Nov 10. pii: S0090-8258(20)34061.
    PubMed     Abstract available


  677. NITECKI R, Fu S, Lefkowits C, Smith BD, et al
    Employment disruption following the diagnosis of endometrial cancer.
    Gynecol Oncol. 2020 Nov 9. pii: S0090-8258(20)34063.
    PubMed     Abstract available


  678. MATSUZAKI S, Klar M, Matsuzaki S, Roman LD, et al
    Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity.
    Gynecol Oncol. 2020 Nov 9. pii: S0090-8258(20)34065.
    PubMed     Abstract available


  679. WALL JA, Meza-Perez S, Scalise CB, Katre A, et al
    Manipulating the Wnt/beta-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
    Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34053.
    PubMed     Abstract available


  680. WESLEY E, Uppendahl LD, Felices M, Dahl C, et al
    Cytomegalovirus and systemic inflammation at time of surgery is associated with worse outcomes in serous ovarian cancer.
    Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34051.
    PubMed     Abstract available


  681. BIZZARRI N, du Bois A, Fruscio R, De Felice F, et al
    Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?
    Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34050.
    PubMed     Abstract available


  682. BLANC-DURAND F, Genestie C, Galende EY, Gouy S, et al
    Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape.
    Gynecol Oncol. 2020 Nov 5. pii: S0090-8258(20)33955.
    PubMed     Abstract available


  683. DIAZ-FEIJOO B, Bebia V, Hernandez A, Gilabert-Estalles J, et al
    Surgical complications comparing extraperitoneal vs transperitoneal laparoscopic aortic staging in early stage ovarian and endometrial cancer.
    Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34060.
    PubMed     Abstract available


  684. LEE EK, Fader AN, Santin AD, Liu JF, et al
    Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies.
    Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34039.
    PubMed     Abstract available


  685. RUSSELL B, Hawarden A, Gee M, Edmondson RJ, et al
    Propensity score matching confirms that primary surgery or neoadjuvant chemotherapy result in equivalent survival within a comprehensive cohort of patients with high-grade serous ovarian cancer.
    Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34057.
    PubMed     Abstract available


  686. RUSSO S, Walker JL, Carlson JW, Carter J, et al
    Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers.
    Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34048.
    PubMed     Abstract available


  687. PEDRA NOBRE S, Hensley ML, So M, Zhou QC, et al
    The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome.
    Gynecol Oncol. 2020 Nov 3. pii: S0090-8258(20)34042.
    PubMed     Abstract available


  688. DE LA MOTTE ROUGE T, Touboul C, Lhomel C, Roupret M, et al
    Factors associated with compliance to cervical cancer screening in France: The EDIFICE 6 survey.
    Gynecol Oncol. 2020 Nov 3. pii: S0090-8258(20)34054.
    PubMed     Abstract available


  689. BREWSTER WR
    Insurance and adherence to guideline concordant cervical cancer therapy do not reduce mortality?
    Gynecol Oncol. 2020;159:297-298.
    PubMed    


  690. YANG J, Delara R, Magrina J, Magtibay P, et al
    Management and outcomes of primary vaginal Cancer.
    Gynecol Oncol. 2020;159:456-463.
    PubMed     Abstract available


  691. BRZEZINSKA BN, Shepherd JP, Rath KS, Clements AE, et al
    A cost-effectiveness analysis of sentinel lymph node detection in vulvar cancer by preoperative lymphoscintigraphy versus intraoperative detection alone.
    Gynecol Oncol. 2020;159:498-502.
    PubMed     Abstract available


    October 2020
  692. RUBINSTEIN MM, Grisham RN, Cadoo K, Kyi C, et al
    A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
    Gynecol Oncol. 2020 Oct 30. pii: S0090-8258(20)34041.
    PubMed     Abstract available


  693. ELAYAPILLAI S, Ramraj S, Benbrook DM, Bieniasz M, et al
    Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer.
    Gynecol Oncol. 2020 Oct 29. pii: S0090-8258(20)34018.
    PubMed     Abstract available


  694. JOU J, Binder P, Saenz C, Eskander R, et al
    Charting a professional course for academic gynecologic oncology mentors.
    Gynecol Oncol. 2020 Oct 29. pii: S0090-8258(20)34046.
    PubMed     Abstract available


  695. CARTER J, Huang HQ, Armer J, Carlson JW, et al
    GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function.
    Gynecol Oncol. 2020 Oct 24. pii: S0090-8258(20)34045.
    PubMed     Abstract available


  696. MATSUO K, Matsuzaki S, Nusbaum DJ, Maoz A, et al
    Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer.
    Gynecol Oncol. 2020 Oct 23. pii: S0090-8258(20)34049.
    PubMed     Abstract available


  697. STINTON C, Fraser H, Al-Khudairy L, Court R, et al
    Testing for lynch syndrome in people with endometrial cancer using immunohistochemistry and microsatellite instability-based testing strategies - A systematic review of test accuracy.
    Gynecol Oncol. 2020 Oct 23. pii: S0090-8258(20)34011.
    PubMed     Abstract available


  698. HAN X, Liu S, Yang G, Hosseinifard H, et al
    Prognostic value of systemic hemato-immunological indices in uterine cervical cancer: A systemic review, meta-analysis, and meta-regression of observational studies.
    Gynecol Oncol. 2020 Oct 19. pii: S0090-8258(20)34019.
    PubMed     Abstract available


  699. HUNG P, Zahnd WE, Brandt HM, Adams SA, et al
    Cervical cancer treatment initiation and survival: The role of residential proximity to cancer care.
    Gynecol Oncol. 2020 Oct 17. pii: S0090-8258(20)34014.
    PubMed     Abstract available


  700. LI Q, Cong R, Wang Y, Kong F, et al
    Naples prognostic score is an independent prognostic factor in patients with operable endometrial cancer: Results from a retrospective cohort study.
    Gynecol Oncol. 2020 Oct 17. pii: S0090-8258(20)34021.
    PubMed     Abstract available


  701. FERRISS JS, Rose S, Rungruang B, Urban R, et al
    Society of Gynecologic Oncology recommendations for fellowship education during the COVID-19 pandemic and beyond: Innovating programs to optimize trainee success.
    Gynecol Oncol. 2020 Oct 17. pii: S0090-8258(20)34017.
    PubMed     Abstract available


  702. SAMOIL D, Abdelmutti N, Gallagher LO, Jivraj N, et al
    Evaluating the effect of a group pre-treatment chemotherapy psycho-education session for chemotherapy-naive gynecologic cancer patients and their caregivers.
    Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)34015.
    PubMed     Abstract available


  703. CEPPI L, Grassi T, Galli F, Buda A, et al
    Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers.
    Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)34036.
    PubMed     Abstract available


  704. HALL MR, Dehbi HM, Banerjee S, Lord R, et al
    A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
    Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)33958.
    PubMed     Abstract available


  705. BARBER EL, Garg R, Persenaire C, Simon M, et al
    Natural language processing with machine learning to predict outcomes after ovarian cancer surgery.
    Gynecol Oncol. 2020 Oct 14. pii: S0090-8258(20)34012.
    PubMed     Abstract available


  706. MORTON M, Chambers LM, Costales AB, Chichura A, et al
    Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2020 Oct 13. pii: S0090-8258(20)33962.
    PubMed     Abstract available


  707. MICHELS J, Genestie C, Dunant A, Caron O, et al
    Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.
    Gynecol Oncol. 2020 Oct 12. pii: S0090-8258(20)33960.
    PubMed     Abstract available


  708. RESHKO LB, Baliga S, Crandley EF, Harry Lomas IV, et al
    Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers.
    Gynecol Oncol. 2020 Oct 12. pii: S0090-8258(20)33967.
    PubMed     Abstract available


  709. HAUNSCHILD CE, Tewari KS
    The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
    Gynecol Oncol. 2020 Oct 11. pii: S0090-8258(20)33953.
    PubMed     Abstract available


  710. CARR C, Son J, Yao M, Priyadarshini A, et al
    Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
    Gynecol Oncol. 2020 Oct 9. pii: S0090-8258(20)33949.
    PubMed     Abstract available


  711. KWON BS, Roh HJ, Lee S, Yang J, et al
    Comparison of long-term survival of total abdominal radical hysterectomy and laparoscopy-assisted radical vaginal hysterectomy in patients with early cervical cancer: Korean multicenter, retrospective analysis.
    Gynecol Oncol. 2020 Oct 8. pii: S0090-8258(20)33945.
    PubMed     Abstract available


  712. NICA A, Lee JYJ, Hong NL, May T, et al
    Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer.
    Gynecol Oncol. 2020 Oct 6. pii: S0090-8258(20)33961.
    PubMed     Abstract available


  713. CORVIGNO S, Mezheyeuski A, De La Fuente LM, Westbom-Fremer S, et al
    High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer.
    Gynecol Oncol. 2020 Oct 5. pii: S0090-8258(20)33951.
    PubMed     Abstract available


  714. CICCONE MA, Adams CL, Bowen C, Thakur T, et al
    Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
    Gynecol Oncol. 2020 Oct 5. pii: S0090-8258(20)33950.
    PubMed     Abstract available


  715. JAREEMIT N, Horowitz NS, Goldstein DP, Berkowitz RS, et al
    Outcomes for relapsed versus resistant low risk gestational trophoblastic neoplasia following single-agent chemotherapy.
    Gynecol Oncol. 2020 Oct 3. pii: S0090-8258(20)33956.
    PubMed     Abstract available


  716. GERSHENSON DM, Cobb LP, Sun CC
    Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for the relative efficacy of tamoxifen and aromatase inhibitors.
    Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33959.
    PubMed    


  717. PRAISS AM, Huang Y, St Clair CM, Tergas AI, et al
    Using machine learning to create prognostic systems for endometrial cancer.
    Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33957.
    PubMed     Abstract available


  718. UBACHS J, Koole SN, Lahaye M, Fabris C, et al
    No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
    Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33952.
    PubMed     Abstract available


  719. ROSSI EC
    Identifying the worst of the worst: HER2 positive early stage uterine papillary serous carcinoma.
    Gynecol Oncol. 2020;159:1-2.
    PubMed    


  720. LENTZ SE, Powell CB, Haque R, Armstrong MA, et al
    Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
    Gynecol Oncol. 2020 Oct 1. pii: S0090-8258(20)33914.
    PubMed     Abstract available


  721. HUH WK
    51st Annual Meeting of the Society of Gynecologic Oncology.
    Gynecol Oncol. 2020;159 Suppl 1:1.
    PubMed    


  722. BAO H, Bi H, Zhang X, Zhao Y, et al
    Artificial intelligence-assisted cytology for detection of cervical intraepithelial neoplasia or invasive cancer: A multicenter, clinical-based, observational study.
    Gynecol Oncol. 2020;159:171-178.
    PubMed     Abstract available


  723. EAKIN CM, Ewongwo A, Pendleton L, Monk BJ, et al
    Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
    Gynecol Oncol. 2020;159:112-117.
    PubMed     Abstract available


  724. SALANI R, Liu JF
    Meeting report from the 2020 Annual (virtual) Meeting of the American Society of Clinical Oncology.
    Gynecol Oncol. 2020;159:13-16.
    PubMed    


  725. CRESTANI A, Benoit L, Touboul C, Pasquier J, et al
    Hyperthermic intraperitoneal chemotherapy (HIPEC): Should we look closer at the microenvironment?
    Gynecol Oncol. 2020;159:285-294.
    PubMed     Abstract available


    September 2020
  726. CYR MP, Dumoulin C, Bessette P, Pina A, et al
    Feasibility, acceptability and effects of multimodal pelvic floor physical therapy for gynecological cancer survivors suffering from painful sexual intercourse: A multicenter prospective interventional study.
    Gynecol Oncol. 2020 Sep 30. pii: S0090-8258(20)33856.
    PubMed     Abstract available


  727. KOTSOPOULOS J, Gronwald J, McCuaig JM, Karlan BY, et al
    Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2020 Sep 30. pii: S0090-8258(20)33947.
    PubMed     Abstract available


  728. CHEN LC, Huang Y, Hou JY, Khoury-Collado F, et al
    Toxicity after adjuvant therapy for stage III uterine cancer.
    Gynecol Oncol. 2020 Sep 29. pii: S0090-8258(20)33943.
    PubMed     Abstract available


  729. STENZEL AE, Moysich KB, Ferrando CA, Starbuck KD, et al
    Clinical needs for transgender men in the gynecologic oncology setting.
    Gynecol Oncol. 2020 Sep 29. pii: S0090-8258(20)33948.
    PubMed     Abstract available


  730. NASIOUDIS D, Albright BB, Roy A, Ko EM, et al
    Patterns of use and outcomes of sentinel lymph node mapping for patients with high-grade endometrial cancer.
    Gynecol Oncol. 2020 Sep 28. pii: S0090-8258(20)33916.
    PubMed    


  731. CHAN JK, Liang SY, Kapp DS, Chan JE, et al
    Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.
    Gynecol Oncol. 2020 Sep 26. pii: S0090-8258(20)33910.
    PubMed    


  732. LANDOLFO C, Achten ETL, Ceusters J, Baert T, et al
    Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.
    Gynecol Oncol. 2020 Sep 26. pii: S0090-8258(20)33918.
    PubMed     Abstract available


  733. ROMERO I, Rubio MJ, Medina M, Matias-Guiu X, et al
    An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study.
    Gynecol Oncol. 2020 Sep 25. pii: S0090-8258(20)33906.
    PubMed     Abstract available


  734. SMITH M, Lara OD, O'Cearbhaill R, Knisely A, et al
    Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infection.
    Gynecol Oncol. 2020 Sep 25. pii: S0090-8258(20)33946.
    PubMed     Abstract available


  735. ALBRIGHT BB, Nasioudis D, Byrne ME, Latif NA, et al
    Perioperative outcomes and disparities in utilization of sentinel lymph node biopsy in minimally invasive staging of endometrial cancer.
    Gynecol Oncol. 2020 Sep 24. pii: S0090-8258(20)33942.
    PubMed     Abstract available


  736. MIRZA MR, Benigno B, Dorum A, Mahner S, et al
    Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
    Gynecol Oncol. 2020 Sep 24. pii: S0090-8258(20)33899.
    PubMed     Abstract available


  737. FREY MK, Fowlkes RK, Badiner NM, Fishman D, et al
    Gynecologic oncology care during the COVID-19 pandemic at three affiliated New York City hospitals.
    Gynecol Oncol. 2020 Sep 24. pii: S0090-8258(20)33898.
    PubMed     Abstract available


  738. WICHMANN C, Klotz DM, Zeiler HJ, Hilger RA, et al
    The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
    Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33911.
    PubMed     Abstract available


  739. MANRRIQUEZ E, Mandelbaum A, Aguayo E, Zakhour M, et al
    Factors associated with high-cost hospitalizations in elderly ovarian cancer patients.
    Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33919.
    PubMed     Abstract available


  740. PERRONE AM, Dondi G, Giunchi S, De Crescenzo E, et al
    COVID-19 free oncologic surgical hub: The experience of reallocation of a gynecologic oncology unit during pandemic outbreak.
    Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33940.
    PubMed     Abstract available


  741. CHARO LM, Jou J, Binder P, Hohmann SF, et al
    Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States.
    Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33915.
    PubMed     Abstract available


  742. JOHNSON KE, Popratiloff A, Fan Y, McDonald S, et al
    Analytic comparison of talc in commercially available baby powder and in pelvic tissues resected from ovarian carcinoma patients.
    Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33921.
    PubMed     Abstract available


  743. LANDY R, Mathews C, Robertson M, Wiggins CL, et al
    A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States.
    Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33850.
    PubMed     Abstract available


  744. CHINO J, Annunziata CM, Beriwal S, Bradfield L, et al
    The ASTRO clinical practice guidelines in cervical cancer: Optimizing radiation therapy for improved outcomes.
    Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33908.
    PubMed    


  745. EAKIN CM, Norton TJ, Monk BJ, Chase DM, et al
    Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer.
    Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33817.
    PubMed     Abstract available


  746. MUSORO JZ, Coens C, Greimel E, King MT, et al
    Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
    Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33900.
    PubMed     Abstract available


  747. KORTEKAAS KE, Bastiaannet E, van Doorn HC, de Vos van Steenwijk PJ, et al
    Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes.
    Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33917.
    PubMed     Abstract available


  748. BANTIE L, Tadesse S, Likisa J, Yu M, et al
    A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33905.
    PubMed     Abstract available


  749. GUNAY G, Kirit HA, Kamatar A, Baghdasaryan O, et al
    The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33857.
    PubMed     Abstract available


  750. RIEDINGER CJ, Kimball KJ, Kilgore LC, Bell CW, et al
    Water only fasting and its effect on chemotherapy administration in gynecologic malignancies.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33901.
    PubMed     Abstract available


  751. MUSTON D, Hettle R, Monberg M, McLaurin KK, et al
    Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33814.
    PubMed     Abstract available


  752. KANBERGS AN, Manning-Geist BL, Pelletier A, Sullivan MW, et al
    Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33904.
    PubMed     Abstract available


  753. JORDAN SE, Saad H, Covarrubias AS, Siemon J, et al
    mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population.
    Gynecol Oncol. 2020 Sep 17. pii: S0090-8258(20)33831.
    PubMed     Abstract available


  754. BOITANO TKL, Sanders LJ, Gentry ZL, Smith HJ, et al
    Decreasing opioid use in postoperative gynecologic oncology patients through a restrictive opioid prescribing algorithm.
    Gynecol Oncol. 2020 Sep 17. pii: S0090-8258(20)33907.
    PubMed     Abstract available


  755. YOSHIMOTO Y, Sasaki Y, Murata K, Noda SE, et al
    Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy.
    Gynecol Oncol. 2020 Sep 17. pii: S0090-8258(20)33821.
    PubMed     Abstract available


  756. CHAMBERS LM, Kuznicki M, Yao M, Chichura A, et al
    Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
    Gynecol Oncol. 2020 Sep 16. pii: S0090-8258(20)33903.
    PubMed     Abstract available


  757. PALMQVIST C, Staf C, Mateoiu C, Johansson M, et al
    Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment.
    Gynecol Oncol. 2020 Sep 15. pii: S0090-8258(20)33897.
    PubMed     Abstract available


  758. DI DONATO V, Di Pinto A, Giannini A, Caruso G, et al
    Modified fragility index and surgical complexity score are able to predict postoperative morbidity and mortality after cytoreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2020 Sep 4. pii: S0090-8258(20)33823.
    PubMed     Abstract available


  759. ZEIMET AG
    Molecular characterization of vulvar squamous cell cancer: High time to gain ground.
    Gynecol Oncol. 2020;158:519-520.
    PubMed    


  760. YANG J, Delara R, Ghaith S, Newman H, et al
    Tumor-free margins and local recurrence in squamous cell carcinoma of the vulva.
    Gynecol Oncol. 2020;158:555-561.
    PubMed     Abstract available


  761. PRIESKE K, Alawi M, Oliveira-Ferrer L, Jaeger A, et al
    Genomic characterization of vulvar squamous cell carcinoma.
    Gynecol Oncol. 2020;158:547-554.
    PubMed     Abstract available


  762. CAO D, Shen K, Chen Y, Xu Y, et al
    Value of endocervical curettage in follow-up for patients with cervical intraepithelial neoplasia stage 2+ after loop electrosurgical excision.
    Gynecol Oncol. 2020;158:584-589.
    PubMed     Abstract available


  763. BERTOLI HK, Baandrup L, Aalborg GL, Kjaer AK, et al
    Time trends in the incidence and survival of vaginal squamous cell carcinoma and high-grade vaginal intraepithelial neoplasia in Denmark - A nationwide population-based study.
    Gynecol Oncol. 2020;158:734-739.
    PubMed     Abstract available


  764. FRUMOVITZ M, Westin SN, Salvo G, Zarifa A, et al
    Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract.
    Gynecol Oncol. 2020;158:570-575.
    PubMed     Abstract available


    August 2020
  765. ZIEBA S, Chechlinska M, Kowalik A, Kowalewska M, et al
    Genes, pathways and vulvar carcinoma - New insights from next-generation sequencing studies.
    Gynecol Oncol. 2020;158:498-506.
    PubMed     Abstract available


    June 2020
  766. VASSEUR D, Lopez J, Croce S, Tondeur G, et al
    Transcriptome profiling of gastric-type endocervical adenocarcinomas identifies key signaling pathways for tumor progression.
    Gynecol Oncol. 2020;157:775-782.
    PubMed     Abstract available


  767. MANCINI S, Bucchi L, Baldacchini F, Giuliani O, et al
    Incidence trends of vulvar squamous cell carcinoma in Italy from 1990 to 2015.
    Gynecol Oncol. 2020;157:656-663.
    PubMed     Abstract available


  768. KILTS TP, Long B, Glasgow AE, Bakkum-Gamez JN, et al
    Invasive vulvar extramammary Paget's disease in the United States.
    Gynecol Oncol. 2020;157:649-655.
    PubMed     Abstract available


  769. CHEN H, Gotimer K, De Souza C, Tepper CG, et al
    Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma.
    Gynecol Oncol. 2020;157:783-792.
    PubMed     Abstract available


  770. DUSKA LR, Petroni GR, Varhegyi N, Brown J, et al
    A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
    Gynecol Oncol. 2020;157:585-592.
    PubMed     Abstract available


  771. SPEKREIJSE JJ, Streng BMM, Vermeulen RFM, Voss FO, et al
    The risk of developing squamous cell carcinoma in patients with anogenital lichen sclerosis: A systematic review.
    Gynecol Oncol. 2020;157:671-677.
    PubMed     Abstract available


    May 2020
  772. PATEL SN, Staples JN, Garcia C, Chatfield L, et al
    Are ethnic and racial minority women less likely to participate in clinical trials?
    Gynecol Oncol. 2020;157:323-328.
    PubMed     Abstract available


  773. STUEBS FA, Mehlhorn G, Gass P, Schulmeyer CE, et al
    Concordance rate of vulvoscopic findings in detecting early vulvar neoplasia.
    Gynecol Oncol. 2020;157:463-468.
    PubMed     Abstract available


  774. POUNDS R, O'Neill D, Subba K, Garg A, et al
    The role of preoperative computerized tomography (CT) scan of the pelvis and groin in the management of clinically early staged vulva squamous cell carcinoma.
    Gynecol Oncol. 2020;157:444-449.
    PubMed     Abstract available


    April 2020
  775. GULTEKIN M, Dundar S, Keskinkilic B, Turkyilmaz M, et al
    How to triage HPV positive cases: Results of four million females.
    Gynecol Oncol. 2020 Apr 30. pii: S0090-8258(20)31008.
    PubMed     Abstract available


  776. REICH O, Regauer S, Kashofer K
    Possibly carcinogenic HPV subtypes are a cause of HSIL and negative clinical HPV tests - A European prospective single center study.
    Gynecol Oncol. 2020 Apr 27. pii: S0090-8258(20)30985.
    PubMed     Abstract available


  777. RASMUSSEN CL, Thomsen LT, Aalborg GL, Kjaer SK, et al
    Incidence of vulvar high-grade precancerous lesions and cancer in Denmark before and after introduction of HPV vaccination.
    Gynecol Oncol. 2020 Apr 7. pii: S0090-8258(20)30255.
    PubMed     Abstract available


  778. SCOTT SA, Llaurado Fernandez M, Kim H, Elit L, et al
    Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes.
    Gynecol Oncol. 2020;157:36-45.
    PubMed     Abstract available


  779. GAULIN NB, Lesnock JL, Tian C, Osei-Bonsu K, et al
    Survival disparities in vulvar cancer patients in Commission on Cancer(R)-accredited facilities.
    Gynecol Oncol. 2020;157:136-145.
    PubMed     Abstract available


  780. NASIOUDIS D, Bhadra M, Ko EM
    Extramammary Paget disease of the vulva: Management and prognosis.
    Gynecol Oncol. 2020;157:146-150.
    PubMed     Abstract available


    February 2020
  781. EVA LJ, Sadler L, Fong KL, Sahota S, et al
    Trends in HPV-dependent and HPV-independent vulvar cancers: The changing face of vulvar squamous cell carcinoma.
    Gynecol Oncol. 2020 Feb 6. pii: S0090-8258(20)30083.
    PubMed     Abstract available


    January 2020
  782. BERTOLI HK, Thomsen LT, Iftner T, Dehlendorff C, et al
    Risk of vulvar, vaginal and anal high-grade intraepithelial neoplasia and cancer according to cervical human papillomavirus (HPV) status: A population-based prospective cohort study.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30082.
    PubMed     Abstract available


  783. LI T, Wu Z, Jiang M, Zhao Y, et al
    Clinical performance of Onclarity HPV assay and Cobas HPV test in detection of cervical precancer and cancer in Chinese women.
    Gynecol Oncol. 2020 Jan 18. pii: S0090-8258(20)30022.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: